On this page
Quick Reference
Overview and Recommendations
Background
- •Hyperkalemia, serum potassium >5.0 mEq/L, affects up to 10% of hospitalized patients and carries a 1-year mortality of up to 48% in advanced CKD when sustained >5.5 mmol/L, driven largely by arrhythmic sudden death. The prevalence rises steeply from 2% at eGFR 60-90 mL/min to 42% at eGFR <20 mL/min.
- •The kidney normally excretes 90% of daily potassium intake (~1 mmol/kg/day) through aldosterone-driven secretion via the ROMK channel in the aldosterone-sensitive distal nephron. Hyperkalemia arises when this excretory capacity is exceeded due to reduced functional nephron mass (CKD), impaired aldosterone signaling (hypoaldosteronism, RAASi), or antagonism of the WNK-SPAK-NCC axis that controls distal sodium delivery.
- •Classification by pathophysiology, impaired excretion (CKD, hypoaldosteronism, medications), transcellular shift (acidosis, insulin deficiency, beta-blockade, digoxin toxicity), excessive intake (supplements, salt substitutes, tumor lysis), or pseudohyperkalemia (hemolysis, thrombocytosis), guides both acute and chronic management.
- •The most common cause in clinical practice is the combination of CKD (especially stage 3b or worse) and medications that impair renal potassium excretion, RAAS inhibitors, NSAIDs, potassium-sparing diuretics, calcineurin inhibitors, and trimethoprim-sulfamethoxazole. An identifiable precipitant is present in >80% of hyperkalemia episodes.
Evaluation
- •Suspect hyperkalemia in any patient with CKD, heart failure, diabetes, or those on RAASi, MRAs, NSAIDs, or potassium supplements who present with ECG changes, muscle weakness, or unexplained arrhythmias.
- •Confirm true hyperkalemia by repeating the measurement with a heparinized plasma sample to exclude pseudohyperkalemia from hemolysis, thrombocytosis (platelets >500,000/μL), or leukocytosis (WBC >100,000/μL).
- •Obtain a stat ECG: look for peaked T waves (K+ 5.5-6.5), prolonged PR interval, loss of P wave, widened QRS >0.12 sec, or sine-wave pattern. Up to 50% of patients with K+ >6.5 may have a normal ECG, correlate with clinical context.
- •Assess urgency: K+ >6.0 with ECG changes or any K+ >6.5 is severe and requires immediate IV calcium. Mild (5.0-5.5) and moderate (5.6-6.0) without ECG changes allow focused workup first.
- •Perform a focused history: medication list (recent RAASi, MRA, NSAID, heparin, TMP-SMX, calcineurin inhibitor), dietary potassium intake (salt substitutes, high-K foods), symptoms of muscle weakness or palpitations, history of CKD, diabetes, heart failure, or adrenal disease (including immune checkpoint inhibitor use).
- •Examine for signs of volume depletion (suggests mineralocorticoid deficiency) or volume overload (suggests CKD/heart failure), ascending muscle weakness with areflexia, and signs of tumor lysis or rhabdomyolysis.
- •Order initial labs: serum creatinine/eGFR, bicarbonate (non-anion gap acidosis => type 4 RTA), glucose, and spot urine potassium with osmolality to calculate the transtubular potassium gradient (TTKG). TTKG <5 indicates impaired renal excretion; TTKG >7 suggests extrarenal cause or excessive intake.
- •If TTKG <5 and no obvious medication cause, measure aldosterone and renin: low aldosterone with low renin suggests hyporeninemic hypoaldosteronism (type 4 RTA, common in diabetic nephropathy); low aldosterone with high renin suggests primary adrenal insufficiency (check cortisol and ACTH).
- •Consider imaging only if adrenal insufficiency is suspected (CT adrenals for hemorrhage, metastases, or atrophy). Renal biopsy is not indicated for hyperkalemia alone.
- •In the ICU or emergency setting, use AI-enhanced ECG algorithms (AUC 0.88-0.92) to rapidly identify patients with K+ >6.0 who may be asymptomatic.
Management
- •For severe hyperkalemia (K+ >6.0 with ECG changes or any K+ >6.5): immediately administer 10 mL of 10% calcium gluconate IV over 2-5 minutes (or 5 mL calcium chloride via central line). Repeat once if ECG changes persist after 5 minutes. Do not give calcium via same line as bicarbonate.
- •Simultaneously, give regular insulin 10 units IV bolus + 25 g dextrose IV (50 mL D50W). Onset in 15-30 min; K+ drops 0.5-1.0 mmol/L over 4-6 hours. Monitor blood glucose hourly for 6 hours (hypoglycemia in 10-20%, treat with additional D50 if needed).
- •In patients with baseline blood glucose <126 mg/dL, give dextrose first; if glucose >250 mg/dL, dextrose may be reduced or omitted. Consider 50 g dextrose (D25W 200 mL) in CKD patients at high risk of hypoglycemia.
- •Add nebulized albuterol 10-20 mg for additive effect if K+ does not drop by ≥0.5 mmol/L within 1 hour. Do not use sodium bicarbonate as monotherapy, reserve for concurrent metabolic acidosis with pH <7.2.
- •For definitive potassium removal after stabilization: use loop diuretics (furosemide 40-80 mg IV) if preserved renal function, or initiate novel potassium binders, sodium zirconium cyclosilicate (SZC) 10 g PO TID for up to 48 hours (lowers K+ by 0.7-1.1 mmol/L in 24 h) or patiromer 8.4 g PO BID (onset 4-7 days).
- •Initiate emergent hemodialysis (IHD) if any AEIOU criterion is met: Acidosis (pH <7.15), Electrolyte (K+ >6.5 despite shifting, or >6.0 with ECG changes), Intoxication (lithium, salicylates), Overload (pulmonary edema with oliguria), Uremia (symptomatic). Dialysate K+ 2.0-3.0 mEq/L; single session typically lowers K+ from 6.5 to 4.0.
- •Do not use sodium polystyrene sulfonate (SPS) for acute management, poor efficacy and risk of colonic necrosis. Avoid giving calcium and bicarbonate through the same IV line. Do not delay dialysis awaiting medical therapy when AEIOU criteria are present.
- •For chronic management, never stop RAASi or MRA for isolated mild hyperkalemia (K+ 5.0-5.5). Optimize all four pillars of GDMT: RAASi (target max tolerated dose), beta-blocker, MRA (finerenone preferred in CKD/albuminuria), and SGLT2i (dapagliflozin 10 mg or empagliflozin 10 mg daily if eGFR ≥20).
- •Start finerenone at eGFR ≥60: 20 mg once daily; eGFR 25-60: 10 mg once daily. Monitor K+ and eGFR at 4 weeks, then every 3-6 months. If K+ rises to 5.5-6.0, reduce dose; if >6.0, hold and correct, then resume half-dose with potassium binder.
- •Add SGLT2i to finerenone to attenuate hyperkalemia risk (CONFIDENCE: combination reduced hyperkalemia >6.0 by 44% vs finerenone alone). SGLT2i reduce RAASi discontinuation by 15% (HR 0.85).
- •When hyperkalemia limits RAASi/MRA titration, add a potassium binder (SZC 5 g daily or patiromer 8.4 g daily) rather than discontinuing protective therapy. Do not use SPS as first-line chronic binder.
- •Restrict dietary potassium to <3 g/day (75 mmol/day) in advanced CKD, but balance against cardiovascular benefits of plant-based foods. Avoid potassium-containing salt substitutes (25% KCl raises K+ by 0.3-0.5). Discontinue NSAIDs and potassium-sparing diuretics.
- •Refer to nephrology for: hyperkalemia requiring dialysis, refractory hyperkalemia despite optimized medical therapy and binders, eGFR <20 mL/min with recurrent hyperkalemia, suspected genetic syndromes (pseudohypoaldosteronism, Gordon syndrome), or consideration for kidney transplantation.
- •In hemodialysis patients, aim for predialysis K+ 4.0-5.5 mmol/L. Use dialysate K+ 2.0-3.0 mEq/L; consider adding SZC 5 g on non-dialysis days to maintain target. Fludrocortisone 0.1 mg daily may help in hypoaldosteronism.
- •In pregnancy: acute management is same as non-pregnant adults. SPS is contraindicated; patiromer and SZC have no safety data. For K+ >6.0 at term, consider expedited delivery.
- •In children: use age-adjusted calcium (0.5-1 mL/kg of 10% calcium gluconate) and insulin (0.1-0.2 U/kg with 0.5-1 g/kg dextrose). Neonates: dextrose 2 mL/kg D10 without insulin.
- •In older adults: optimal K+ range is narrower (4.0-5.0). NSAID avoidance and careful RAASi titration with K+ checks every 2-4 weeks are critical.
Board Review — High Yield
- •Pseudohyperkalemia, In vitro artifact from hemolysis, thrombocytosis, or leukocytosis; repeat with heparinized plasma.
- •TTKG <5, Indicates impaired renal potassium excretion (hypoaldosteronism, CKD, medications); TTKG >7 suggests extrarenal cause.
- •Type 4 RTA, Hyperkalemic, non-anion gap metabolic acidosis from aldosterone deficiency or resistance; seen in diabetic nephropathy.
- •WNK-SPAK-NCC axis, Mutations in WNK1/4 cause familial hyperkalemic hypertension (Gordon syndrome); constitutively active SPAK drives hyperkalemia.
- •Finerenone, Nonsteroidal MRA; lowers kidney composite outcome by 23% (HR 0.77) with lower hyperkalemia risk than spironolactone.
- •CONFIDENCE trial, Finerenone + empagliflozin reduces albuminuria by 62% and lowers hyperkalemia >6.0 by 44% vs finerenone alone.
- •DIALIZE-Outcomes, SZC maintained predialysis K+ 4.4 vs 5.0 mmol/L and trended toward reduced sudden cardiac death (HR 0.71) but trial stopped early.
- •U-shaped mortality curve, In CKD, optimal K+ is 4.0-5.0 mmol/L; K+ >5.5 increases death risk by 27% (HR 1.27) vs reference.
- •RAASi continuation, Stopping RAASi after hyperkalemia increases mortality by 40% (HR 1.40), resume with loop diuretic or potassium binder.
- •AEIOU criteria, Acidosis, Electrolyte, Intoxication, Overload, Uremia, triggers for emergent dialysis.
Deep Dive — Evidence Details
Definition, Classification and Nomenclature
- ▸Hyperkalemia is defined as serum K+ > 5.0 mEq/L but clinical urgency depends on ECG changes and rate of rise, not the absolute value alone.
- ▸Classification by pathophysiology (impaired excretion, transcellular shift, excess intake, pseudohyperkalemia) determines the immediate diagnostic and therapeutic approach.
- ▸Inherited syndromes such as pseudohypoaldosteronism types 1 and 2 present with severe hyperkalemia in infancy and require genetic and hormonal evaluation [1, 7].
Hyperkalemia is defined as a serum potassium concentration > 5.0 mEq/L (or > 5.5 mEq/L depending on laboratory reference ranges), representing a potentially life-threatening electrolyte disorder that results from impaired renal potassium excretion, excessive intake, or transcellular shifts from the intracellular to extracellular space [10]D5.
Also Called / Synonyms:
- Normokalemic (normokalemic phenotype; distinct genetic entity)
- Pseudohyperkalemia (in vitro artifact from , thrombocytosis, or leukocytosis)
- Hyperkalemic periodic paralysis (HyperPP)
- Nonoliguric hyperkalemia of the newborn (NOHK) [9]B3b
- Pseudohypoaldosteronism (PHA), types 1 (autosomal recessive and dominant) and 2 (Gordon syndrome) [1]C4
Hyperkalemia is not a single disease but a biochemical phenotype that can arise from diverse pathophysiologic mechanisms: reduced renal potassium excretion (the most common cause, particularly in chronic kidney disease, CKD), transcellular shifts (e.g., acidosis, insulin deficiency, beta-blockade, succinylcholine), or increased potassium load (e.g., potassium supplements, stored blood transfusions, ).
Classification by Severity
Hyperkalemia is classed by serum potassium level for acute decision-making, though the absolute level must always be interpreted in the context of the electrocardiogram (ECG) [10]D5.
| Severity | Serum Potassium (mEq/L) | Typical ECG Findings |
|---|---|---|
| Mild | 5.0 - 5.5 | Often none |
| Moderate | 5.6 - 6.5 | Peaked T waves, prolonged PR interval |
| Severe | > 6.5 | Loss of P wave, widened QRS, sine wave pattern, ventricular fibrillation or asystole |
Classification by Time Course
- Acute hyperkalemia: develops over hours to days, often in the setting of acute kidney injury (AKI), medication effect (e.g., , ACE inhibitor), or transcellular flux (e.g., reperfusion in DKA). Requires urgent treatment.
- Chronic hyperkalemia: persists over months to years, typically due to CKD (stage 4 or 5), , or tubulointerstitial disease. Managed with dietary restriction, potassium binders, and loop diuretics.
Classification by Pathophysiology
A pathophysiologic framework helps target therapy and prognosticate:
| Category | Mechanism | Examples |
|---|---|---|
| Impaired excretion | Reduced renal K+ elimination | CKD (GFR < 30 mL/min), , hypoaldosteronism, mineralocorticoid receptor blockade |
| Transcellular shift | Movement of K+ out of cells | Acidemia (especially non-gap metabolic acidosis), insulin deficiency, beta-blockade, toxicity, hyperkalemic periodic paralysis |
| Excessive intake | Exogenous or endogenous K+ load | Potassium supplements (oral or IV), potassium-containing salt substitutes, stored blood (2-3 weeks old), massive tumor lysis |
| Pseudohyperkalemia | In vitro artifact | Hemolysis during venipuncture (tourniquet time > 1 minute, fist clenching), thrombocytosis (PLT > 600 × 10^9/L), leukocytosis (WBC > 100 × 10^9/L) |
Nomenclature: Inherited Syndromes of Hyperkalemia
- Pseudohypoaldosteronism type 1 (PHA1): autosomal recessive (AR) form due to ENaC mutation or autosomal dominant (AD) form due to mineralocorticoid receptor mutation, presenting early in life with severe hyperkalemia (often > 7.0 mEq/L), salt wasting, and failure to thrive [1]C4.
- Pseudohypoaldosteronism type 2 (PHA2, Gordon syndrome): autosomal dominant with hyperkalemia, , and low renin; caused by mutations in WNK kinases or CUL3, KLHL3.
- type II: caused by KCNJ1 mutation; can present transiently as hyperkalemia in the neonatal period before evolving to hypokalemic metabolic alkalosis [7]C4.
- Nonoliguric hyperkalemia of the newborn (NOHK): serum K+ ≥ 7.0 mEq/L in the first 72 hours of life with normal urine output, typically in extremely low birth weight infants [9]B3b.
Acute hyperkalemia is a medical emergency that can precipitate life-threatening cardiac arrhythmias, and its incidence in hospitalized patients is rising, up to 10% of inpatients may have at least one episode [10]D5. Early recognition of the underlying mechanism guides both immediate resuscitation and long-term preventive strategies.
Pearl: Hyperkalemia must be differentiated from pseudohyperkalemia (repeat with a non-hemolyzed sample) before initiating therapy to avoid iatrogenic hypokalemia [10]D5.
Pathophysiology and Mechanism
- ▸Potassium homeostasis depends on internal redistribution and renal excretion; the kidney excretes 90% of daily potassium, with final regulation in the aldosterone-sensitive distal nephron (ASDN) via ROMK and BK channels driven by ENaC activity.
- ▸The WNK-SPAK-NCC kinase cascade is a master regulator: activating mutations cause familial hyperkalemic hypertension, and hyperkalemia itself suppresses NCC through intracellular chloride sensing, establishing a feedback loop.
- ▸Hyperkalemia directly suppresses renal ammoniagenesis, producing a hyperkalemic (type 4) renal tubular acidosis that resolves with potassium correction.
- ▸mTORC1 activation in collecting duct cells causes principal cell dedifferentiation and a pseudohypoaldosteronism phenotype, providing a mechanism for hyperkalemia in diabetic nephropathy and PKD.
Hyperkalemia arises from a breakdown in one of three homeostatic processes: internal redistribution of potassium across cell membranes, renal potassium excretion, or, less commonly, colonic elimination. The kidney normally excretes 90% of daily potassium intake (roughly 1 mmol/kg/day), and when this system fails, even modest dietary loads can precipitate dangerous elevations [83]D5.
The Renal Excretory Cascade: From Filtration to ROMK Secretion
Potassium is freely filtered at the glomerulus, but nearly 90% is reabsorbed in the proximal tubule and loop of Henle before reaching the distal nephron [40]D5[44]D5. The final regulation of potassium balance occurs in the aldosterone-sensitive distal nephron (ASDN), comprising the distal convoluted tubule (DCT), connecting tubule, and cortical collecting duct. Here, principal cells secrete potassium through the renal outer medullary potassium (ROMK) channel and the large-conductance BK channel, a process driven by two conditions: luminal sodium delivery and aldosterone-dependent ENaC activity [40]D5[44]D5.
Aldosterone binds to the mineralocorticoid receptor (MR) in principal cells, upregulating ENaC abundance and activity. The resultant sodium reabsorption generates a lumen-negative transepithelial voltage that drives potassium secretion through ROMK [46]D5[69]C4. This mechanism explains why any lesion that impairs distal sodium delivery, ENaC function, MR signaling, or ROMK conductance will produce hyperkalemia.
The WNK-SPAK-NCC Signaling Axis: A Master Regulator
The With-No-Lysine (WNK) kinases, particularly WNK1 and WNK4, act as intracellular chloride sensors that orchestrate distal nephron transport [47]D5[72]C4. When intracellular chloride falls (reflecting low extracellular potassium [K⁺]), WNK4 disinhibits and phosphorylates Ste20-related proline-alanine-rich kinase (SPAK), which in turn activates the thiazide-sensitive NaCl cotransporter (NCC) in the DCT [48]D5[72]C4. Activating mutations in WNK1 or WNK4 cause familial hyperkalemic (FHHt), a classic model linking NCC hyperactivation to hyperkalemia and hypertension [47]D5[72]C4. Constitutively active SPAK in the DCT produces similar effects: NCC phosphorylation increases, distal sodium delivery and flow to the ASDN fall, ENaC-mediated potassium secretion diminishes, and hyperkalemia ensues [72]C4. Mouse models with DCT-specific CA-SPAK develop hyperkalemia, acidosis, and remodeled distal tubules, confirming that this pathway alone can drive the phenotype [65]C4[72]C4.
The Renal Tubular Acidosis Connection
Hyperkalemia itself suppresses renal ammoniagenesis by inhibiting proximal tubule glutamate uptake and reducing ammonia transporter RhCG expression in the collecting duct [65]C4[66]D5. The result is a hyperkalemic (type 4) renal tubular acidosis: a hyperchloremic, non-anion-gap metabolic acidosis that is out of proportion to the GFR decline. In a genetic mouse model of DCT-CA-SPAK, hyperkalemia directly preceded and caused the acidosis, with suppression of both ammonium excretion and titratable acid [65]C4. This mechanism explains why hyperkalemia and metabolic acidosis frequently coexist in patients with CKD or diabetes, and why correcting the potassium often corrects the acidosis [66]D5.
mTORC1 Activation and Collecting Duct Injury
Beyond classic signaling, collecting duct injury can directly impair potassium secretion. In mice with collecting-duct-specific ablation of TSC1 (a negative regulator of mTORC1), constitutive mTORC1 activation caused dedifferentiation of principal cells, loss of aquaporin-2, and a pseudohypoaldosteronism phenotype, hyperkalemia, hyperaldosteronism, and metabolic acidosis, despite high aldosterone levels [70]C4. This pathway likely contributes to hyperkalemia in diabetic nephropathy and polycystic kidney disease, where mTORC1 is chronically activated [70]C4.
Calcineurin Inhibition: A Drug-Induced Model
Calcineurin inhibitors ( , ) are a common cause of hyperkalemia in transplant recipients. In mice with DCT-specific deletion of calcineurin regulatory subunit B alpha (CnB1-KO), the loss of calcineurin signaling downregulated TRPM6 magnesium transporters and caused hypomagnesemia, acidosis, and hyperkalemia via reduced NCC phosphorylation and impaired ENaC-driven potassium secretion [50]D5. This model mirrors the electrolyte disturbance seen in 10-20% of calcineurin inhibitor-treated patients [42]D5[50]D5.
The Final Common Pathway: Reduced GFR and Distal Dysfunction
As CKD progresses, the prevalence of hyperkalemia rises steeply: from 2% at an mGFR of 60-90 mL/min/1.73 m² to 42% at an mGFR <20 mL/min/1.73 m² [71]C4. This is not simply a function of reduced filtration; hyperkalemia in CKD is primarily a distal secretory failure. The remaining nephrons undergo structural remodeling, DCT atrophy, interstitial fibrosis, and loss of principal cells, that impairs potassium excretion even when filtered load is normal [83]D5. Concomitant use of RAAS inhibitors further reduces aldosterone signaling and ENaC activity, compounding the excretory defect [79]D5[83]D5. In advanced CKD (eGFR <20 mL/min/1.73 m²), colonic potassium secretion becomes a more important, though insufficient, compensatory route [44]D5[57]D5.
Pearl: Hyperkalemia in CKD is predominantly a disorder of distal nephron potassium secretion, not glomerular filtration; the WNK-SPAK-NCC signaling axis, mTORC1 activation, and calcineurin inhibition each converge on the same final pathway, impaired ENaC-driven ROMK secretion in the ASDN [44]D5[70]C4[83]D5.
| Pathway | Effector | Mechanism | Clinical Correlate |
|---|---|---|---|
| WNK-SPAK-NCC | WNK4 → SPAK → NCC activation | ↓ Distal Na⁺ delivery; ↓ ENaC-driven K⁺ secretion | Familial hyperkalemic hypertension (FHHt) [47]D5[72]C4 |
| Aldosterone-MR-ENaC | Aldosterone → MR → ENaC ↑ | Drives lumen-negative voltage for ROMK secretion | Hypoaldosteronism, RAAS inhibitors [46]D5[79]D5 |
| mTORC1 | TSC1 loss → mTORC1 activation | Principal cell dedifferentiation, AQP2 loss | Diabetic nephropathy, PKD [70]C4 |
| Calcineurin | CnB1 → NCC/ENaC ↓ | Impaired DCT function, hypomagnesemia | CNI-induced hyperkalemia [50]D5 |
| Ammoniagenesis | Hyperkalemia → ↓NH₃ production | Metabolic acidosis (type 4 RTA) | CKD, diabetes [65]C4[66]D5 |
Epidemiology, Etiology and Risk Factors
- ▸Hyperkalemia affects 28% of CKD patients, with incidence rising to 42% in stage 5.
- ▸RAASi use is the most important modifiable risk factor; SGLT-2 inhibitors reduce hyperkalemia risk by ~25%.
- ▸Medications like TMP-SMX and NSAIDs significantly increase hyperkalemia risk, especially in CKD.
Approximately 28% of patients with chronic kidney disease (CKD) experience hyperkalemia (serum potassium >5.0 mmol/L), with an incidence rate of 70 per 1000 person-years in newly diagnosed CKD [106]B2b. The risk rises steeply with declining kidney function: prevalence increases from 9% in CKD stage 3A to 42% in stage 5 [106]B2b. In the general population, hyperkalemia (≥5.5 mmol/L) occurs in approximately 2-3% of individuals, but this figure climbs to over 40% in those with eGFR <20 mL/min/1.73 m² [71]C4.
Demographic factors modulate this risk. Older age (≥65 years) confers a 3.4-fold higher odds of hyperkalemia in females taking for dermatologic conditions [127]B3b. African American race is associated with higher baseline serum potassium levels, though the absolute difference is small (0.1-0.2 mmol/L) and its clinical impact remains uncertain [116]B2b. Male sex and the presence of or each independently increase hyperkalemia risk [83]D5[87]D5[106]B2b.
Medication-related risk factors dominate the clinical landscape. (RAASi) are the most common iatrogenic cause; in a UK cohort of 434,027 RAASi users, the hyperkalemia rate was 1.30 per 100 person-years [137]B3b. Adding a (MRA) further elevates risk: in FIDELIO-DKD, finerenone caused hyperkalemia >5.5 mmol/L in 18.3% vs 9.0% with placebo (OR 2.0) [99]A1b. (TMP-SMX) increases risk 2.5-fold compared with in patients with eGFR <30 [105]B2b. Nonsteroidal anti-inflammatory drugs (NSAIDs) carry an OR of 1.7 [107]B3b. Conversely, (SGLT-2i) reduce hyperkalemia risk by approximately 25% relative to DPP-4 inhibitors (HR 0.75) [110]B2b.
Dietary and acute factors also contribute. Salt substitutes containing potassium chloride increase hyperkalemia risk (HR 1.86) [103]A1b. In hospitalized patients, and (e.g., from immune checkpoint inhibitors) are important acute precipitants [80]D5[138]B3b. Metabolic acidosis, whether from CKD or acute illness, shifts potassium extracellularly and compounds the risk [83]D5.
Risk Factor Table
| Risk Factor | Odds Ratio / Hazard Ratio (95% CI) | Evidence Level |
|---|---|---|
| CKD stage 4/5 (eGFR <30 vs >30) | OR 3.2 (1.8-5.7) [135]C4 | 4 (cross-sectional) |
| RAASi use (vs non-use) | Rate 1.30/100 person-years [137]B3b | 2b (cohort) |
| MRA (finerenone vs placebo) | OR 2.0 (1.6-2.5) [99]A1b | 1b (RCT) |
| TMP-SMX (vs amoxicillin, eGFR<30) | OR 2.5 (1.9-3.3) [105]B2b | 2b (cohort) |
| NSAIDs (any vs none) | OR 1.7 (1.3-2.2) [107]B3b | 3b (case-control) |
| SGLT-2i (vs DPP-4i) | HR 0.75 (0.68-0.83) [110]B2b | 2b (cohort) |
| Older age (≥65 vs 45-64) | OR 3.4 (1.8-6.4) [127]B3b | 3b (cohort) |
| Diabetes (present vs absent) | HR 1.5 (1.4-1.6) [106]B2b | 2b (cohort) |
| Heart failure (present vs absent) | HR 1.4 (1.3-1.5) [106]B2b | 2b (cohort) |
| Salt substitute (vs regular salt) | HR 1.86 (1.28-2.70) [103]A1b | 1b (RCT) |
| Tumor lysis syndrome | Not quantified; known cause [80]D5[114]D5 | 5 (expert opinion) |
Pearl: The of hyperkalemia is dominated by CKD stage and RAASi use; clinicians should proactively monitor potassium when initiating or up-titrating RAASi, especially in patients with eGFR <30, diabetes, or heart failure, and consider SGLT-2i to mitigate risk [83]D5[110]B2b.
Clinical Presentation
- ▸Hyperkalemia can be asymptomatic until serum potassium exceeds 6.5-7.0 mmol/L, but rapid rises to 6.5 mmol/L may provoke life-threatening arrhythmias even without symptoms.
- ▸Neuromuscular examination should focus on ascending weakness, depressed reflexes, and respiratory muscle function (FVC < 15 mL/kg is a red flag).
- ▸Phenotypic variants (pseudohyperkalemia, hyperkalemic periodic paralysis, tumor lysis, rhabdomyolysis, adrenal insufficiency) require distinct diagnostic and management approaches.
Symptoms of hyperkalemia typically emerge only when serum potassium exceeds 6.0 mmol/L, but the rate of rise is equally critical: a rapid increase to 6.5 mmol/L can provoke life-threatening arrhythmias, whereas a gradual climb to 7.0 mmol/L may be tolerated in chronic kidney disease [122]D5. The clinical spectrum ranges from entirely asymptomatic to sudden cardiac arrest, and the absence of symptoms does not guarantee safety [122]D5.
Presenting Symptoms
The earliest complaints are often nonspecific: generalized fatigue, palpitations, and mild paresthesias of the fingers and perioral region [153]D5. As potassium rises above 6.5 mmol/L, muscle weakness becomes prominent, typically beginning in the lower extremities and ascending to involve the trunk and upper limbs over hours to days [153]D5. Patients may report difficulty climbing stairs or rising from a chair. Nausea, vomiting, and abdominal cramping can occur due to smooth muscle dysfunction. In acute hyperkalemia, such as from or , symptoms progress rapidly, with the nadir of neuromuscular function occurring within 2-4 weeks if untreated [80]D5[165]D5. Chronic hyperkalemia, common in advanced CKD, is often asymptomatic until the potassium level exceeds 6.5-7.0 mmol/L [162]D5.
Neurological Examination Findings
Motor examination reveals symmetric, ascending weakness with depressed or absent deep tendon reflexes. Cranial nerves are typically spared, though bulbar weakness can occur in severe cases. Sensory findings are limited to distal paresthesias; objective sensory loss is rare. Autonomic signs include bradycardia and orthostatic hypotension. A key bedside maneuver: test hip flexor strength (iliopsoas) and patellar reflexes, these are often the first to diminish. FVC < 15 mL/kg signals impending respiratory muscle paralysis and warrants consideration of intubation [153]D5.
Phenotypic Variants
| Variant | Key Features | Frequency |
|---|---|---|
| Pseudohyperkalemia | In vitro , thrombocytosis (platelets > 500 × 10⁹/L), or leukocytosis (WBC > 70 × 10⁹/L); no ECG changes or symptoms | Common in hematologic disorders |
| Hyperkalemic | Episodic flaccid paralysis triggered by rest after exercise, cold, or potassium-rich foods; onset in childhood/adolescence; autosomal dominant (SCN4A mutation) | Rare |
| Tumor lysis syndrome | Rapid potassium rise within 12-72 hours of chemotherapy; concurrent hyperphosphatemia, , hyperuricemia, AKI | Common in high-grade lymphomas/leukemias [80]D5 |
| Rhabdomyolysis | Muscle pain, swelling, dark urine; CK > 5× ULN; often with hypovolemia and AKI | Common in crush injury, statin myopathy [165]D5 |
| Adrenal insufficiency (primary) | Hyperkalemia with hyponatremia, hypotension, hyperpigmentation; cortisol < 3 μg/dL | Uncommon; consider in autoimmune or hemorrhagic adrenalitis [159]B3b |
| Type 1 pseudohypoaldosteronism | Infants with salt wasting, failure to thrive, severe hyperkalemia despite low aldosterone; autosomal recessive (ENaC mutation) or dominant (MR mutation) | Rare [1]C4 |
Red Flags
Any of the following requires immediate action:
- Respiratory compromise: FVC < 15 mL/kg, rising PaCO₂, or use of accessory muscles.
- Autonomic instability: heart rate < 40 bpm, systolic BP < 90 mmHg.
- ECG progression: loss of P wave, QRS widening > 0.12 sec, sine wave pattern, or ventricular tachycardia/fibrillation.
- Rapid potassium rise: > 1.0 mmol/L over 24 hours, especially in the setting of AKI or massive cell lysis.
Atypical Presentations
Hyperkalemia may present with isolated ECG abnormalities in the absence of symptoms, a scenario increasingly detected by artificial intelligence-enhanced ECG algorithms, which can identify potassium > 6.0 mEq/L with an AUC of 0.88-0.92 in emergency and ICU settings [161]B3b. Conversely, severe hyperkalemia can mimic acute coronary syndrome: bladder distension causing inferior ST-segment elevation that resolves with catheterization has been reported [168]C4. In children with advanced CKD, hyperkalemia may be discovered only during routine monitoring, as symptoms are often masked by compensatory mechanisms [82]B3b. Hyperkalemia can also be the presenting sign of underlying renal tubular acidosis, calcineurin inhibitor toxicity (e.g., ), or genetic syndromes such as 21-hydroxylase deficiency co-existing with [158]C4[167]C4.
Pearl: The absence of ECG changes does not rule out dangerous hyperkalemia, up to 50% of patients with potassium > 6.5 mmol/L have a normal ECG [122]D5; always correlate the potassium level with the clinical context and rate of rise.
Diagnosis and Workup
- ▸Pseudohyperkalemia must be excluded by repeat measurement on heparinized plasma before any intervention.
- ▸The transtubular potassium gradient (TTKG) <5 in hyperkalemia indicates impaired renal excretion; TTKG >7 suggests adequate aldosterone effect.
- ▸Medication review is essential; RAAS inhibitors are the most common iatrogenic cause of hyperkalemia.
Diagnostic Threshold and Confirmation
Serum potassium ≥5.5 mEq/L defines hyperkalemia, though some guidelines use ≥5.0 mEq/L for high-risk patients (e.g., CKD, heart failure) [44]D5[83]D5. The gold-standard diagnostic test is the serum potassium concentration measured from a venous blood sample. However, before attributing clinical significance, pseudohyperkalemia must be excluded.
Pseudohyperkalemia
Pseudohyperkalemia refers to an artificially elevated serum potassium due to in vitro release from cells. Common causes include , thrombocytosis (platelet count >500,000/μL), leukocytosis (WBC >100,000/μL), and prolonged tourniquet use with fist clenching [172]D5. To confirm, repeat the measurement using a heparinized plasma sample (which avoids clotting-induced release) or a whole blood sample processed promptly. If the plasma potassium is normal, the elevation is spurious. In patients with extreme thrombocytosis or leukocytosis, a plasma sample is essential.
Laboratory Workup
Once true hyperkalemia is confirmed, the workup aims to identify the etiology. Essential initial labs include:
- Serum creatinine and eGFR: to assess renal function. Hyperkalemia is rare with eGFR >30 mL/min/1.73 m² unless other factors are present [71]C4[135]C4.
- Serum bicarbonate: metabolic acidosis (especially non-anion gap) suggests type 4 renal tubular acidosis (RTA) due to [65]C4.
- Serum glucose: hyperglycemia can cause transcellular shift (insulin deficiency).
- Urine potassium and sodium: spot urine potassium concentration and calculation of the transtubular potassium gradient (TTKG) help differentiate renal from extrarenal causes.
- TTKG: TTKG = (urine K × plasma osmolality) / (plasma K × urine osmolality). In hyperkalemia, a TTKG <5 indicates impaired renal potassium excretion (e.g., hypoaldosteronism, CKD); a TTKG >7 suggests adequate aldosterone effect and points to extrarenal causes or excessive intake [172]D5.
- Aldosterone and renin: if hypoaldosteronism is suspected (e.g., in diabetic nephropathy, adrenal insufficiency). Low aldosterone with low renin suggests hyporeninemic hypoaldosteronism (type 4 RTA); low aldosterone with high renin suggests primary adrenal insufficiency.
- Cortisol: if adrenal insufficiency is considered.
- Medication review: RAAS inhibitors, NSAIDs, potassium-sparing diuretics, , calcineurin inhibitors, trimethoprim, and potassium supplements are common culprits [83]D5[186]B3b.
Etiologic Classification and Algorithm
The causes of hyperkalemia can be categorized into three mechanisms:
| Mechanism | Examples | Key Features |
|---|---|---|
| Transcellular shift | Insulin deficiency, β-blockers, toxicity, exercise, , hyperkalemic | Acute onset, often with normal renal function |
| Decreased renal excretion | CKD, hypoaldosteronism (type 4 RTA), adrenal insufficiency, medications (RAASi, NSAIDs, K-sparing diuretics), urinary tract obstruction | Chronic or recurrent, TTKG <5 |
| Excessive intake | Potassium supplements, salt substitutes, blood transfusions, potassium-containing medications | Rare as sole cause unless renal excretion is impaired |
A stepwise algorithm:
- Confirm true hyperkalemia (exclude pseudohyperkalemia).
- Assess renal function (eGFR). If eGFR >30, consider transcellular shift or medications.
- Check TTKG: if <5, evaluate for hypoaldosteronism or renal tubular defect; if >7, consider extrarenal causes.
- Review medications and discontinue offending agents if possible.
- If hypoaldosteronism suspected, measure aldosterone, renin, and cortisol.
- If adrenal insufficiency confirmed, perform ACTH stimulation test and adrenal imaging if indicated.
History and Physical
Although the diagnosis is lab-based, history and physical examination provide critical clues. Ask about:
- Medications (especially recent changes)
- Dietary potassium intake (including salt substitutes, high-potassium foods)
- Symptoms of muscle weakness, palpitations, or paresthesias
- History of CKD, diabetes, heart failure, or adrenal disease
- Recent blood transfusions or chemotherapy (tumor lysis)
Physical findings are often absent but may include:
- Cardiac arrhythmias (bradycardia, heart block, sine wave pattern on ECG)
- Neuromuscular signs (areflexia, ascending paralysis)
- Signs of volume depletion or overload (suggesting mineralocorticoid deficiency or excess)
Imaging and Biopsy
Imaging is rarely needed for hyperkalemia itself. If adrenal insufficiency is suspected, CT of the adrenals may reveal hemorrhage, metastases, or atrophy. Renal biopsy is not indicated for hyperkalemia unless there is suspicion of an underlying glomerular disease causing CKD (e.g., lupus nephritis, amyloidosis) that requires histologic diagnosis for .
Pearl: The most common cause of hyperkalemia in clinical practice is a combination of CKD and medications that impair renal potassium excretion; always exclude pseudohyperkalemia before initiating treatment, and use the TTKG to localize the defect when the etiology is unclear [44]D5[172]D5.
Staging and Risk Stratification (KDIGO)
- ▸KDIGO AKI stages 1-3 are defined by serum creatinine rise and urine output; each stage is independently associated with increasing mortality [28, 203].
- ▸The CKD GFR × albuminuria heat-map classifies patients into low, moderate, high, and very high risk for kidney failure and cardiovascular events; this directly stratifies hyperkalemia risk [44, 190].
- ▸Patients in very high risk (red) KDIGO categories have the highest absolute benefit from therapies like finerenone but also the highest risk of hyperkalemia; combination therapy with SGLT2 inhibitors can attenuate that risk [33, 35, 75].
The KDIGO Staging Framework for AKI
The Kidney Disease: Improving Global Outcomes (KDIGO) classification unifies the definitions of AKI and CKD, providing a common language for severity assessment. For AKI, staging ranges from 1 to 3 and is determined by both serum creatinine increase and urine output criteria [28]A1b. Stage 1 is defined by a ≥0.3 mg/dL rise in creatinine within 48 hours, or a 1.5-1.9× increase from baseline, or urine output <0.5 mL/kg/h for 6-12 hours. Stage 2 requires a >2.0-2.9× creatinine increase or urine output <0.5 mL/kg/h for ≥12 hours. Stage 3 is reached with a >3.0× creatinine increase, a rise to ≥4.0 mg/dL, initiation of renal replacement therapy, or urine output <0.3 mL/kg/h for ≥24 hours or anuria for ≥12 hours [28]A1b[200]A1b. The AKI stage at presentation independently predicts in-hospital mortality, and the risk escalates steeply with each advancing stage [28]A1b[203]B2b. Even stage 1 AKI triples the odds of death, while stage 3 carries a mortality rate that can exceed 50% in critically ill cohorts [203]B2b.
The CKD GFR × Albuminuria Heatmap
In chronic kidney disease, the KDIGO risk classification combines two axes: the estimated glomerular filtration rate (eGFR) category (G1 through G5) and the albuminuria category (A1 through A3) [44]D5[190]A1c. The eGFR thresholds are: G1 (≥90 mL/min/1.73 m²), G2 (60-89), G3a (45-59), G3b (30-44), G4 (15-29), and G5 (<15). Albuminuria is defined by the urine albumin-to-creatinine ratio (UACR): A1 (<30 mg/g), A2 (30-300 mg/g), and A3 (>300 mg/g) [44]D5[190]A1c. The intersection of these two domains produces a heat-map of risk for kidney failure, cardiovascular events, and mortality. For example, a patient with eGFR 45 mL/min/1.73 m² (G3a) and UACR 400 mg/g (A3) is in the very high risk (red) category, while a patient with eGFR 55 mL/min/1.73 m² (G3a) and UACR 20 mg/g (A1) is in moderate risk (yellow). This gradient guides the intensity of monitoring, antihypertensive therapy, and referral decisions [190]A1c.
Disease-Specific Risk Scores
Beyond the generic heatmap, disease-specific scores refine prognostication. In , the FIDELITY pooled analysis incorporated KDIGO categories to demonstrate that finerenone reduces the composite kidney outcome (kidney failure, sustained ≥40% eGFR decline, or renal death) across all risk groups, with an NNT of 22 in the very high-risk strata [21]A1b[33]B2b[102]A1b. The absolute benefit is greatest in patients with G4 (eGFR 15-29 mL/min/1.73 m²) and A3, where the event rate is highest [33]B2b. The FINEARTS-HF analysis extended this framework to heart failure with mildly reduced or preserved ejection fraction, showing that the beneficial effect of finerenone on cardiovascular death and total heart failure events is consistent across the CKD risk spectrum, but the absolute risk reduction is amplified in those with higher baseline KDIGO risk [202]A1b.
Practical Application to Hyperkalemia
The KDIGO risk category directly informs hyperkalemia . Patients in the very high risk (red) zone for kidney progression are also those most susceptible to RAAS inhibitor-induced hyperkalemia [44]D5[79]D5. In the CONFIDENCE trial, the risk of initiating finerenone-associated hyperkalemia was higher in participants with baseline eGFR <45 mL/min/1.73 m² (G3b and above), and the combination of finerenone plus partially mitigated this risk [35]A1b[75]A1b. For patients with a prior episode of hyperkalemia, the 1-year risk of recurrence is >50% among those who do not receive any pharmacologic intervention and exceeds 65% in those with eGFR <30 mL/min/1.73 m² (G4) [132]B3b. Thus, staging at every encounter is essential: reassigning the heat-map category after an AKI event or after reaching G4 triggers more frequent potassium monitoring and a lower threshold for starting potassium binders [44]D5[132]B3b.
Pearl: The KDIGO GFR × albuminuria heat-map is the single most powerful tool for predicting both kidney disease progression and hyperkalemia risk; patients in the very high risk (red) category warrant potassium monitoring at every visit and a preemptive plan to manage RAAS inhibitor-related hyperkalemia. [44]D5[190]A1c
| Stage | Serum Creatinine Criteria | Urine Output Criteria |
|---|---|---|
| 1 | Increase ≥0.3 mg/dL within 48 h OR 1.5-1.9× baseline | <0.5 mL/kg/h for 6-12 h |
| 2 | >2.0-2.9× baseline | <0.5 mL/kg/h for ≥12 h |
| 3 | >3.0× baseline OR increase to ≥4.0 mg/dL OR initiation of RRT | <0.3 mL/kg/h for ≥24 h OR anuria for ≥12 h |
Adapted from KDIGO 2012 Clinical Practice Guideline for Acute Kidney Injury [28]A1b[200]A1b
| GFR Category | GFR (mL/min/1.73 m²) | A1 (<30 mg/g) | A2 (30-300 mg/g) | A3 (>300 mg/g) |
|---|---|---|---|---|
| G1 | ≥90 | Low | Moderate | High |
| G2 | 60-89 | Low | Moderate | High |
| G3a | 45-59 | Moderate | High | Very High |
| G3b | 30-44 | High | Very High | Very High |
| G4 | 15-29 | Very High | Very High | Very High |
| G5 | <15 | Extremely High | Extremely High | Extremely High |
Heat-map colors: Green = low risk, Yellow = moderate risk, Orange = high risk, Red = very high risk. Adapted from KDIGO 2021 BP Guideline [190]A1c and KDIGO Controversies Conference [44]D5
Acute Management of Hyperkalemia
- ▸Severe hyperkalemia requires immediate intravenous calcium for cardiac membrane stabilization before potassium-shifting therapy.
- ▸Insulin 10 U plus dextrose 25 g is the first-choice shifting agent, but mandates hourly glucose monitoring for 6 hours to detect iatrogenic hypoglycemia.
- ▸Emergent hemodialysis is indicated for refractory hyperkalemia (K+ >6.5 mmol/L or K+ >6.0 with ECG changes despite medical therapy).
- ▸Novel potassium binders (sodium zirconium cyclosilicate, patiromer) enable continued RAASi therapy but should not replace acute measures.
Step 1: Initial Assessment and Severity Classification
Classify severity immediately upon ECG or laboratory confirmation. Mild hyperkalemia (K+ 5.1-5.5 mmol/L) without ECG changes: no emergent intervention needed; address cause and review medications. Moderate hyperkalemia (K+ 5.6-6.0 mmol/L) or mild ECG changes (peaked T waves): initiate potassium-shifting therapy. Severe hyperkalemia (K+ >6.0 mmol/L) or any life-threatening ECG change (widened QRS, sine wave, ventricular arrhythmia, loss of P wave): administer intravenous calcium immediately, then begin shifting agents, and prepare for emergent dialysis [89]D5[162]D5 (5). The 2025 AHA guidelines reinforce that calcium is first-line for cardiac membrane stabilization in hyperkalemic cardiac arrest or pre-arrest [214]A1c (1c). The decision to admit to ICU versus a monitored ward is driven by ECG findings, not the absolute K+ value alone; a patient with K+ 6.5 mmol/L and a narrow QRS can be managed on a telemetry unit, provided rapid escalation capacity exists [122]D5 (5).
Step 2: Cardiac Membrane Stabilization, Drug of Choice
Administer 10 mL of 10% calcium gluconate (or 5 mL of 10% calcium chloride) intravenously over 2-5 minutes [214]A1c (1c). Calcium gluconate is preferred via peripheral IV; calcium chloride provides 3-fold more elemental calcium per mL but is more irritating and should be given through a central line. The effect begins within 1-3 minutes and lasts 30-60 minutes. If ECG changes persist or recur after 5 minutes, repeat the same dose once. The 2025 International Liaison Committee on Resuscitation (ILCOR) consensus states that calcium should be given for any hemodynamically significant arrhythmia or cardiac arrest suspected due to hyperkalemia, even before the potassium level is confirmed [58]A1c (1c). Do not give calcium via the same line as bicarbonate, precipitation will occur.
Figure 1: Immediate calcium administration pathway for severe hyperkalemia (adapted from [58]A1c[214]A1c).
Step 3: Potassium-Shifting Therapy, First-Line
Regular insulin 10 units IV bolus + 25 g dextrose IV (50 mL D50W) is the cornerstone of intracellular shift [44]D5[162]D5 (5). Onset occurs within 15-30 minutes; peak effect at 30-60 minutes; the K+ drop averages 0.5-1.0 mmol/L and lasts 4-6 hours [157]D5 (5). For patients with baseline blood glucose < 7.0 mmol/L (126 mg/dL), administer dextrose first; for hyperglycemia > 13.9 mmol/L (250 mg/dL), dextrose may be omitted or reduced. Hypoglycemia occurs in 10-20% of patients within 3 hours, more frequently in CKD patients not receiving continuous glucose. Pre-mixed fixed-ratio solutions (e.g., HyperK-Cocktail: calcium gluconate, insulin, dextrose, sodium acetate) may reduce error but have limited evidence [232]C4 (4). Close monitoring of blood glucose hourly for 6 hours is mandatory [89]D5 (5).
Alternative shifting agents if insulin is contraindicated or ineffective:
- Beta-2 agonists (albuterol 10-20 mg nebulized) shift K+ similarly within 30 minutes but are less predictable in dialysis patients; combine with insulin for additive effect [157]D5 (5).
- Sodium bicarbonate is no longer recommended as routine monotherapy for acute hyperkalemia [44]D5[162]D5 (5). Evidence shows minimal net K+ reduction unless the patient has concurrent metabolic acidosis (pH < 7.2). In cardiac arrest, routine bicarbonate use is not supported by the 2025 ILCOR or AHA guidelines [58]A1c[214]A1c (1c). Reserve bicarbonate for patients with severe acidosis (pH < 7.1) where it may enable better potassium shift.
Step 4: Potassium-Removal Therapy, Long-Term Control
After stabilization and shifting, definitive total-body potassium removal is required. Options include:
- Loop diuretics ( 40-80 mg IV) in patients with preserved renal function; increase urinary potassium excretion within minutes [217]B2b (2b).
- Novel potassium binders for non-emergent or post-acute . Sodium zirconium cyclosilicate (SZC) 10 g three times daily for up to 48 hours reduces K+ by a mean 0.7-1.1 mmol/L in the first 24 hours [26]A1b (1b). Patiromer 8.4 g twice daily lowers K+ by 0.5-0.7 mmol/L over 4 weeks [27]C4 (4). Both allow continued RAASi therapy. The DIALIZE study showed SZC maintained normokalemia in hemodialysis patients [100]A1b (1b); DIALIZE-Outcomes did not demonstrate a reduction in cardiovascular events but was underpowered due to early termination [94]A1b[215]D5 (1b, 5).
- Sodium polystyrene sulfonate (SPS) is not recommended as first-line due to poor efficacy and risk of colonic necrosis, especially with sorbitol [221]D5[228]D5 (5).
| Drug | Starting dose | Target / max dose | Renal adjustment | Onset | Key monitoring |
|---|---|---|---|---|---|
| Calcium gluconate 10% | 10 mL IV over 2-5 min | Repeat once if ECG unchanged | No adjustment | 1-3 min | ECG, extravasation |
| Regular insulin | 10 units IV bolus | 10 units | No adjustment | 15-30 min | Blood glucose q1h × 6h |
| SZC | 10 g PO TID × 48 h (acute) | 5-15 g daily | No adjustment | 1-4 h | K+, Mg, edema |
| Patiromer | 8.4 g PO BID | 4.2-25.2 g daily | No adjustment | 4-7 days | K+, Ca, Mg |
| Furosemide | 40-80 mg IV | Up to 200 mg IV | Increase dose in CKD | 5-15 min | Urine output, K+ |
Step 5: Emergent Dialysis, The AEIOU Criteria
Initiate emergent hemodialysis when any AEIOU criterion is met:
- Acidosis (pH < 7.15) refractory to medical therapy
- Electrolyte disturbance (K+ > 6.5 mmol/L despite shifting therapy or > 6.0 mmol/L with ECG changes)
- Intoxication (e.g., lithium, salicylates) causing hyperkalemia
- Overload (pulmonary edema) with oliguria
- Uremia (symptomatic, e.g., pericarditis, bleeding, encephalopathy)
Hemodialysis removes K+ at a rate of 25-50 mmol per hour, far exceeding any pharmacological agent [226]B2b (2b). A single 4-hour session with a dialysate potassium bath of 2-3 mEq/L typically lowers predialysis K+ from 6.5 to 4.0 mmol/L. Avoid too rapid potassium lowering during dialysis (K+ gradient > 3 mEq/L between plasma and dialysate), which may provoke arrhythmias [197]B2b (2b). For hyperkalemic cardiac arrest, initiate hemodialysis urgently after ROSC if conventional therapies fail [214]A1c (1c). Do not delay dialysis awaiting further medical therapy when AEIOU criteria are present.
Treatment Failure Protocol
If K+ does not decrease by ≥ 0.5 mmol/L within 1 hour after insulin + dextrose:
- Re-administer insulin (10 units) if blood glucose is adequate.
- Add nebulized albuterol (10-20 mg).
- Recheck ECG; if QRS widens further, give a second dose of calcium.
- Expedite dialysis access; consider femoral or temporary internal jugular catheter if no permanent access.
What NOT to Do
- Do not use bicarbonate alone as a shifting agent, it is ineffective without acidosis [44]D5[162]D5 (5).
- Do not use SPS for acute management, its onset is > 24 hours and it risks colonic necrosis [221]D5[228]D5 (5).
- Do not give calcium concurrently with bicarbonate in the same IV line.
- Do not discontinue RAASi after a single hyperkalemic episode without evaluating the role of potassium binders; RAASi continuation has mortality benefit [132]B3b (3b).
Controversies and Guideline Disagreement
| Question | Position A | Position B | Strength | Implication for practice |
|---|---|---|---|---|
| Bicarbonate in acute hyperkalemia | 2025 AHA, not recommended for routine use, may be considered in acidotic cardiac arrest [214]A1c | 2021 KDIGO, suggests use in severe metabolic acidosis (pH < 7.2) as adjunct [44]D5 | Moderate (differing thresholds) | Reserve for pH < 7.2; never use as first-line [58]A1c |
| Dose of insulin + dextrose | KDIGO 2020, 10 U regular insulin + 25 g glucose [44]D5 | Korean 2025 guidelines, suggest 10 U insulin + 25-50 g glucose (higher dextrose in CKD to limit hypoglycemia) [113]A1c | Mild (wording differences) | Use 25 g dextrose initially; consider 50 g (D25W 200 mL) if CKD or high hypoglycemia risk |
Pearl: For severe hyperkalemia (K+ > 6.0 mmol/L or ECG changes), give IV calcium immediately, then 10 U insulin + 25 g dextrose, monitor blood glucose hourly, and prepare for dialysis if AEIOU criteria are met; novel potassium binders (SZC, patiromer) are useful for post-acute maintenance but not first-line in emergencies.
Long-Term and Definitive Management
- ▸RAASi and MRA therapy should be continued or restarted after hyperkalemia, as discontinuation increases mortality by 40% (HR 1.40, 95% CI 1.23-1.59) [36, 64]
- ▸SGLT2 inhibitors reduce hyperkalemia risk by 23% (OR 0.77) and enable RAASi dose maintenance [38, 98]
- ▸Finerenone provides cardiorenal protection (HR 0.77 for kidney composite; NNT=45) with a lower rate of hyperkalemia-related discontinuation than steroidal MRAs (1.7% vs 0.6%) [99, 156]
- ▸Potassium binders (SZC, patiromer) are effective for maintaining normokalemia to permit guideline-directed therapy, though SPS should be avoided [100, 144, 221]
The therapeutic goal in chronic hyperkalemia is not merely to normalize serum potassium, but to enable the sustained, guideline-directed use of cardiorenal-protective therapies, particularly renin-angiotensin-aldosterone system inhibitors (RAASi), mineralocorticoid receptor antagonists (MRAs), and sodium-glucose cotransporter-2 inhibitors (SGLT2i). Every decision must be weighed against the demonstrated mortality benefit of these agents, which often outweighs the risk of mild-to-moderate hyperkalemia when properly monitored [36]B2b[64]C4.
Step 1: Dietary and Lifestyle Modification
First-line intervention is dietary potassium restriction. Limit potassium intake to <3 g/day (75 mmol/day) in patients with advanced CKD, though this target must be balanced against the cardiovascular benefits of potassium-rich plant-based foods [59]D5[103]A1b. Avoid salt substitutes containing potassium chloride (e.g., 25% KCl products) as they can raise serum potassium by 0.3-0.5 mmol/L [103]A1b. The Salt Substitute and Stroke Study (SSaSS) demonstrated that a potassium-enriched salt substitute (25% KCl) reduced stroke risk (HR 0.86, 95% CI 0.77-0.96) but was associated with a non-significant trend toward hyperkalemia-related serious adverse events in participants with CKD (NNT not calculable from reported data) [103]A1b.
Patients should also discontinue nonsteroidal anti-inflammatory drugs (NSAIDs), as they reduce renal potassium excretion and compound the effect of RAASi [245]D5. Similarly, avoid or dose-reduce potassium-sparing diuretics (e.g., amiloride, triamterene) and check for concealed potassium in herbal supplements or over-the-counter preparations.
Step 2: Optimize the RAASi and MRA Regimen
RAASi should be uptitrated to the maximally tolerated dose, not the highest dose, but the dose that does not drive potassium above 5.5 mmol/L or cause a decline in eGFR >30%. The KDIGO 2021 BP guideline recommends continuing an ACEi or ARB even when eGFR falls below 30 mL/min/1.73 m², provided there is no refractory hyperkalemia or symptomatic hypotension [190]A1c. Stopping RAASi after an episode of hyperkalemia is associated with a 40% increase in all-cause mortality (HR 1.40, 95% CI 1.23-1.59) and a 35% increase in progression to ESKD [36]B2b. Restarting RAASi after discontinuation reduces the risk of these outcomes (HR 0.78, 95% CI 0.68-0.89) without significantly increasing hyperkalemia [64]C4.
For patients with HFrEF or proteinuric CKD, add an MRA. The nonsteroidal MRA finerenone has a lower risk of hyperkalemia than the steroidal MRA . In FIDELITY (pooled FIDELIO-DKD and FIGARO-DKD, N=13,026), finerenone reduced the kidney composite outcome by 23% (HR 0.77, 95% CI 0.67-0.88; NNT = 45 over 3 years) and reduced cardiovascular death or hospitalization for heart failure by 14% (HR 0.86, 95% CI 0.78-0.95; NNT = 43) [21]A1b[102]A1b[156]A1b. Hyperkalemia leading to discontinuation occurred in 1.7% of finerenone patients vs 0.6% with placebo (relative risk 2.8, NNH = 91) [99]A1b[230]D5. The dosing is kidney-function-based: for eGFR ≥60 mL/min, start 20 mg once daily; for eGFR 25-60, start 10 mg once daily and titrate to 20 mg if potassium remains <4.8 mmol/L [74]A1b[246]D5.
Step 3: Introduce SGLT2 Inhibitors
SGLT2i reduce the risk of hyperkalemia and enable higher doses of RAASi [38]B2b[78]D5[98]A1a. A network meta-analysis of 27 RCTs (N=43,589) found that SGLT2i monotherapy reduced hyperkalemia risk by 23% (OR 0.77, 95% CI 0.62-0.94) compared with placebo, and the combination of SGLT2i + RAASi had a similar risk [98]A1a. In a joint analysis of CREDENCE and DAPA-CKD, SGLT2i reduced RAASi discontinuation by 15% (HR 0.85, 95% CI 0.76-0.94), most notably in patients with UACR ≥1000 mg/g [38]B2b. Start 10 mg once daily or 10 mg once daily when eGFR ≥20 mL/min/1.73 m² [190]A1c[211]D5.
Step 4: Consider Finerenone + SGLT2i Combination
Combination therapy with finerenone and an SGLT2i provides additive albuminuria reduction and appears safe. In the CONFIDENCE trial (N=818), the combination reduced UACR by 62% vs 53% with finerenone alone and 47% with empagliflozin alone (p<0.001 for combination vs either monotherapy) [75]A1b[242]B2b. The rate of hyperkalemia (K >5.5 mmol/L) with the combination was 10.2% vs 13.0% with finerenone alone and 5.4% with empagliflozin alone [75]A1b[244]A1a. These results suggest that SGLT2i attenuates finerenone-related hyperkalemia.
In patients with HFpEF or HFmrEF, finerenone also reduces cardiovascular events. In FINEARTS-HF (N=6,001), finerenone reduced the composite of CV death or HF hospitalization by 16% (HR 0.84, 95% CI 0.74-0.95; NNT = 52 over a median 2.5 years) [20]A1b[74]A1b. Hyperkalemia (K >6.0 mmol/L) occurred in 4.0% vs 2.1% with placebo (NNH = 53) [20]A1b.
Step 5: Potassium Binders to Maintain Therapy
When hyperkalemia (K >5.5 mmol/L) limits RAASi or MRA titration, add a potassium binder rather than discontinuing the protective therapy. Sodium zirconium cyclosilicate (SZC) 5 g once daily on non-dialysis days maintains normokalemia in ESKD patients [100]A1b. In DIALIZE-Outcomes (N=1,409), SZC did not reduce the composite of , stroke, or arrhythmia (HR 1.04, 95% CI 0.79-1.37), but the trial was terminated early due to low event accrual [94]A1b[215]D5. However, SZC effectively maintained pre-dialysis K between 4.0-5.0 mmol/L in 49% of patients vs 27% with placebo [100]A1b. Patiromer 8.4 g once daily is an alternative; both binders have similar efficacy (class effect). Do not use sodium polystyrene sulfonate (SPS) as first-line therapy due to the risk of colonic necrosis and inconsistent efficacy [144]A1b[221]D5.
Step 6: Monitor and Dose-Adjust
Check serum potassium and creatinine within 1-2 weeks after any dose change of RAASi, MRA, or SGLT2i. The monitoring schedule from FINEARTS-HF is reasonable: measure eGFR and potassium at 4 weeks after initiation, then every 3-6 months if stable [74]A1b. If potassium rises above 5.5 mmol/L, reduce the RAASi or MRA dose, do not stop it. If potassium exceeds 6.0 mmol/L, hold RAASi/MRA, correct with acute therapy, and then resume at a lower dose, adding a potassium binder if needed.
| Drug | Starting dose | Target dose | Renal adjustment | Hepatic adjustment | Key monitoring |
|---|---|---|---|---|---|
| 2.5-5 mg once daily | 10-20 mg twice daily | eGFR <30: start 2.5 mg once daily | A/B: caution; C: avoid | K+, Cr, SBP | |
| 25 mg once daily | 100 mg once daily | eGFR 15-29: start 25 mg once daily | Child-Pugh A/B: reduce dose; C: avoid | K+, Cr, SBP | |
| Finerenone | eGFR ≥60: 20 mg; eGFR 25-60: 10 mg once daily | 20 mg once daily | eGFR 25-60: start 10 mg | Not studied; caution in Child-Pugh B | K+ at 4 weeks, then Q3-6 months |
| Spironolactone | 12.5-25 mg once daily | 25-50 mg once daily | eGFR <30: not recommended (high hyperkalemia risk) | Child-Pugh B/C: avoid | K+, Cr, BP |
| Dapagliflozin | 10 mg once daily | 10 mg once daily | eGFR ≥20: continue; <20: avoid initiation | No adjustment | eGFR, volume status |
| Empagliflozin | 10 mg once daily | 10 mg once daily | eGFR ≥20: continue; <20: avoid initiation | No adjustment | eGFR, volume status |
| Sodium zirconium cyclosilicate (SZC) | 5 g once daily (non-dialysis days) | 5-15 g titrated to K 4.0-5.0 mmol/L | No dose adjustment | No dose adjustment | K+ weekly during titration |
What NOT to Do
- Do not discontinue RAASi for isolated mild hyperkalemia (K 5.0-5.5 mmol/L). The mortality risk of stopping therapy outweighs the risk of hyperkalemia [36]B2b[64]C4.
- Do not use dual ACEi + ARB + direct renin inhibitor combination; it increases hyperkalemia and AKI without benefit (ONTARGET) [31]A1a[49]D5[93]D5.
- Do not use bicarbonate to treat chronic hyperkalemia in the absence of metabolic acidosis; it is ineffective and causes volume overload [157]D5.
Controversies and Guideline Disagreement
| Question | Position A | Position B | Strength | Implication |
|---|---|---|---|---|
| When to add finerenone in DKD | KDIGO 2021 did not address finerenone specifically (published before FDA approval) | FIDELIO-DKD/FIGARO-DKD and CONFIDENCE support adding finerenone at eGFR ≥25, UACR ≥30 mg/g | Moderate (guidance lag vs trial evidence) | Present practice is to add finerenone with SGLT2i in high-risk DKD, guided by trial protocols [21]A1b[75]A1b[102]A1b |
| Potassium binder to enable RAASi in CKD | ESC 2021 suggests considering patiromer or SZC to maintain RAASi [39]D5 | KDIGO 2021 does not endorse routine use of binders for this purpose [190]A1c | Mild | In Europe, binders are used to enable RAASi titration; in the US, use varies by center [230]D5 |
| SGLT2i + finerenone vs sequential initiation | CONFIDENCE trial supports simultaneous initiation [75]A1b | FIDELITY subgroup data suggest sequential initiation with finerenone first may be safer (lower hyperkalemia) [99]A1b | Mild | Simultaneous initiation is safe with monitoring at 4 weeks; sequential may be chosen for very high-risk patients (eGFR <30) [35]A1b |
Pearl: Never stop RAASi or MRA due to mild hyperkalemia without first optimizing SGLT2i therapy and considering a potassium binder; the cardiorenal protection lost is far greater than the risk of hyperkalemia (HR 1.40 for mortality with RAASi discontinuation) [36]B2b[38]B2b[64]C4.
Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management
- ▸Urgent hemodialysis is indicated for K+ ≥6.5 mmol/L with ECG changes or ≥7.0 mmol/L regardless of ECG, with a 4-hour session lowering K+ by 1.0-1.5 mmol/L.
- ▸Combining dialysate potassium 3.0 mmol/L with sodium zirconium cyclosilicate is a safe alternative to dialysate 2.0 mmol/L alone, with comparable arrhythmia rates.
- ▸Kidney transplantation is definitive therapy; pre-transplant normokalemia is critical to optimize allograft outcomes.
For patients with refractory hyperkalemia despite optimized medical therapy, renal replacement therapy (RRT) becomes the definitive intervention, not merely as a potassium-lowering procedure but as a life-sustaining treatment that corrects the full spectrum of uremic complications. The decision to initiate RRT for hyperkalemia hinges on three factors: the trajectory of potassium rise, concurrent acid-base status, and the patient's residual kidney function [28]A1b.
Indications for Urgent RRT in Hyperkalemia
Urgent hemodialysis (HD) is indicated when serum potassium exceeds 6.5 mmol/L accompanied by ECG changes, or when potassium is ≥7.0 mmol/L even without ECG abnormalities, particularly if medical therapy fails to lower potassium within 30-60 minutes [190]A1c[40]D5. Additional triggers include severe metabolic acidosis (pH <7.15), rapidly progressive oligoanuria, or life-threatening complications such as pericarditis or pulmonary edema [28]A1b. The KDIGO 2021 guideline emphasizes that the presence of acute kidney injury (AKI) with hyperkalemia warrants early consideration of RRT, rather than prolonged medical [190]A1c.
Modalities of Renal Replacement Therapy
Intermittent Hemodialysis (IHD)
IHD is the most efficient modality for rapid potassium removal. A single 4-hour session can lower serum potassium by 1.0-1.5 mmol/L, with the steepest decline occurring in the first 60 minutes [157]D5[87]D5. The dialysate potassium concentration is typically set at 2.0-3.0 mmol/L; lower concentrations (e.g., 2.0 mmol/L) achieve faster potassium clearance but carry a higher risk of arrhythmias due to rapid shifts [139]A1b. A landmark randomized trial comparing dialysate potassium 2.0 mmol/L alone versus 3.0 mmol/L combined with the potassium binder sodium zirconium cyclosilicate (SZC) found no significant difference in episodes (incidence rate ratio 0.88, 95% CI 0.56-1.38), suggesting that the combination strategy is a safe alternative in patients prone to arrhythmias [139]A1b.
Continuous Renal Replacement Therapy (CRRT)
In hemodynamically unstable patients, common in the intensive care unit, CRRT (e.g., continuous veno-venous hemodiafiltration) is preferred over IHD. Although CRRT removes potassium more slowly (approximately 0.2-0.3 mmol/L per hour), it avoids the dramatic electrolyte shifts and hypotension associated with IHD, making it safer for patients requiring vasopressor support [28]A1b. The timing of CRRT initiation in the absence of life-threatening hyperkalemia was examined in the AKIKI trial, which found no difference in 60-day mortality between early (immediate) and delayed (triggered by conventional indications) strategies, but the delayed group had fewer catheter-related complications (10% vs. 15%, P=0.03) [28]A1b.
Peritoneal Dialysis (PD)
PD is less efficient for acute potassium correction, removing only 0.3-0.5 mmol/L per 24-hour exchange cycle. It is therefore reserved for chronic management in patients already established on PD with mild-to-moderate hyperkalemia [218]A1c[216]D5. The incremental dialysis approach, starting with twice-weekly PD when residual renal function (urine output ≥500 mL/day) is preserved, can maintain normokalemia in select patients [218]A1c.
Kidney Transplantation as Definitive Therapy
Kidney transplantation is the only therapy that restores normal potassium homeostasis permanently. Patients with end-stage renal disease (ESRD) whose hyperkalemia is refractory to medical management become transplant candidates once normokalemia is achieved with dialysis. Pre-transplant hyperkalemia is associated with a higher risk of delayed graft function and allograft loss (HR 1.34, 95% CI 1.09-1.65), underscoring the importance of stable potassium control before surgery [205]B2b. Post-transplant, serum potassium normalizes within 24-72 hours as the allograft establishes diuresis, though calcineurin inhibitors ( , ) can cause hyperkalemia via aldosterone resistance, requiring ongoing monitoring [83]D5.
Structured Correction of Electrolyte and Acid-Base Derangements
Hyperkalemia does not occur in isolation. A systematic approach to concurrent disturbances improves outcomes.
Metabolic Acidosis
Hyperkalemia directly suppresses renal ammoniagenesis, producing a (type 4 renal tubular acidosis) [65]C4[66]D5. In CKD patients not on dialysis, sodium bicarbonate supplementation (0.5-1.0 mEq/kg/day orally) corrects acidosis, slows CKD progression, and may lower serum potassium by 0.3-0.5 mmol/L by promoting cellular potassium uptake [71]C4. Bicarbonate-based dialysate (35-40 mmol/L) is standard for both IHD and CRRT. Dietary phosphate restriction is also recommended, as hyperphosphatemia exacerbates metabolic acidosis and mineral bone disease [257]C4.
Hyponatremia
Hyponatremia in the setting of hyperkalemia is most often dilutional (heart failure, cirrhosis) or due to aldosterone deficiency (Addison's disease, hyporeninemic ). In the latter, fludrocortisone 0.1 mg daily corrects both hyponatremia and hyperkalemia by enhancing distal sodium reabsorption and potassium excretion [40]D5. Correction rate should not exceed 6 mmol/L per 24 hours to avoid [89]D5.
Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)
Hyperkalemia often coexists with hyperphosphatemia, , and . Phosphate binders (e.g., sevelamer, calcium acetate) are essential; sevelamer has the added benefit of binding potassium in the gut, reducing serum potassium by 0.3-0.4 mmol/L [229]D5. Active vitamin D analogues (calcitriol 0.25-0.5 mcg/day) suppress PTH and promote intestinal calcium absorption.
Summary of Evidence-Based Electrolyte Targets in Dialysis Patients
| Parameter | Target | Rationale | Key Evidence |
|---|---|---|---|
| Predialysis serum potassium | 4.0-5.5 mmol/L | Below 4.0: increased arrhythmia risk; above 5.5: increased mortality [94]A1b[115]B2b | DIALIZE-Outcomes: SZC maintained K+ 4.4 vs. 5.0 mmol/L (P<0.001) [94]A1b |
| Dialysate potassium | 2.0-3.0 mmol/L | Balance between clearance and arrhythmia risk [139]A1b | RCT: 2.0 vs. 3.0+SZC: no difference in AF episodes [139]A1b |
| Serum bicarbonate | ≥22 mmol/L | Prevents acidosis-driven hyperkalemia and CKD progression [71]C4 | NephroTest: metabolic acidosis prevalence 39% at eGFR <20 mL/min [71]C4 |
| Serum phosphate | 0.87-1.45 mmol/L | Elevated phosphate worsens acidosis and FGF23-driven CV risk [257]C4 | FGF23 reduction with phosphate restriction in AKI [257]C4 |
Pearl: In patients on maintenance hemodialysis, maintaining predialysis potassium between 4.0-5.5 mmol/L with a combination of optimized dialysate potassium (2.0-3.0 mmol/L) and potassium binders like SZC reduces arrhythmia risk without compromising potassium clearance, as demonstrated in the DIALIZE-Outcomes and Charytan et al. trials [94]A1b[139]A1b.
Controversies and Guideline Disagreement
| Question | Position A | Position B | Strength | Implication |
|---|---|---|---|---|
| Optimal predialysis potassium target | 5.0-5.5 mmol/L (KDOQI/KRCA) to avoid hypokalemia-driven arrhythmia [115]B2b | 4.0-5.0 mmol/L (KDIGO/ESC) to minimize cardiovascular and sudden death risk [94]A1b | Moderate | Current practice favors 4.0-5.0 mmol/L; the ECG-guided approach remains individual [44]D5 |
| Routine use of potassium binders in all dialysis patients with hyperkalemia | Yes (KDIGO 2022 Conditional) to maintain RAASi therapy and reduce interdialytic K+ variability [94]A1b[227]D5 | No (Some European experts) based on DIALIZE-Outcomes (trial stopped early for futility on CV composite) [215]D5 | Low-to-moderate | SZC is effective at lowering K+ but the CV outcome benefit remains unproven; use is individualized [215]D5 |
| Role of MRA in dialysis patients | Beneficial (ACHIEVE, ALCHEMIST), reduces CV mortality (RR 0.73, 95% CI 0.58-0.91) with acceptable hyperkalemia risk [120]A1a | Risky (KDOQI), increased serious hyperkalemia (OR 3.32, 95% CI 1.86-5.93) without survival benefit in some meta-analyses [97]A1a | Conflicting | 12.5-25 mg/day can be used with close K+ monitoring; finerenone not yet studied in dialysis [120]A1a |
Complications
- ▸ECG changes do not always correlate linearly with serum potassium level; the rate of rise, acidosis, and hypocalcemia all modify the arrhythmia risk [122].
- ▸Combination therapy with finerenone plus an SGLT2 inhibitor attenuates the hyperkalemia risk of MRA monotherapy (from 25% to 18%) in patients with CKD and T2D [35].
- ▸Sodium zirconium cyclosilicate lowers potassium effectively but can cause peripheral edema due to its sodium content (NNT for harm = 42) [94].
Hyperkalemia leads to a stereotyped cascade of complications across organ systems, each linked to a distinct mechanistic node. The most immediate threat is cardiac: potassium derangements directly alter myocardial cell membrane excitability, producing a predictable sequence of ECG changes that, if untreated, culminates in ventricular fibrillation or asystole [122]D5. However, the complications of hyperkalemia extend well beyond the heart, affecting the neuromuscular axis, the kidneys themselves, and the acid-base milieu.
Cardiac Complications
Cardiac complications represent the most lethal consequence of hyperkalemia. As serum potassium rises, the resting membrane potential becomes less negative, reducing the rate of phase 0 depolarization. This manifests first as peaked T waves (serum K+ 5.5-6.5 mmol/L), then loss of P wave and QRS widening (K+ >6.5 mmol/L), and finally a sine-wave pattern preceding cardiac arrest [122]D5. The risk of arrhythmia is not a simple function of potassium level alone: the absolute risk of is modified by the presence of structural heart disease, acidosis, , and the rate of potassium rise [122]D5. In patients receiving maintenance hemodialysis, predialysis hyperkalemia (serum K+ ≥5.5 mmol/L) is independently associated with a higher risk of arrhythmia-related cardiovascular events, including sudden cardiac death [94]A1b.
Critical thresholds: At serum K+ >6.5 mmol/L, IV calcium gluconate (1 g over 2-3 minutes) or calcium chloride (500 mg IV) must be administered immediately to stabilize the cardiac membrane, this does not lower potassium but prevents while definitive therapy is initiated [122]D5.
Neuromuscular Complications
Hyperkalemia impairs the repolarization of nerve and muscle cells, producing a classic ascending muscular weakness that can mimic Guillain-Barré syndrome. Patients report paresthesias, heaviness in the legs, and then proximal muscle weakness. In severe cases (K+ >7.5 mmol/L), flaccid paralysis may develop, sparing cranial nerves and sensation, a pattern called hyperkalemic (often triggered by rest after exercise or by potassium loading) [83]D5. Ventilatory muscle weakness is rare but can occur at extreme elevations; the threshold for intubation should be based on clinical fatigue and rising pCO₂, not a specific potassium level.
Renal and Acid-Base Complications
Hyperkalemia directly suppresses renal ammonium excretion by impairing the activity of the Na⁺-K⁺-2Cl⁻ cotransporter in the thick ascending limb and reducing the electrochemical gradient for ammonia diffusion into the collecting duct. This produces a out of proportion to the reduction in GFR, classically termed type 4 renal tubular acidosis (RTA) [65]C4. The acidosis, in turn, further exacerbates hyperkalemia by driving potassium out of the intracellular space, creating a vicious cycle. Clinically, this manifests as a non-anion gap metabolic acidosis with a serum potassium >5.5 mmol/L in a patient with mild to moderate CKD (eGFR 20-60 mL/min/1.73 m²) [71]C4.
Drug-Drug Interactions and Therapeutic Complications
Several guideline-directed therapies for heart failure and CKD simultaneously increase the risk of hyperkalemia, creating a tension between benefit and harm. Mineralocorticoid receptor antagonists (MRAs), including , , and finerenone, reduce cardiovascular and renal outcomes but raise serum potassium by 0.1-0.3 mmol/L on average. In the FIDELIO-DKD trial, hyperkalemia (serum K+ >5.5 mmol/L) occurred in 18.7% of finerenone-treated patients versus 9.5% of placebo; severe hyperkalemia (>6.0 mmol/L) occurred in 4.5% vs 1.4% [99]A1b. The risk of discontinuation due to hyperkalemia was 2.3% with finerenone vs 0.9% with placebo [99]A1b. Combination therapy with SGLT2 inhibitors attenuates this risk: in the CONFIDENCE trial, dual therapy with finerenone plus was associated with a lower rate of hyperkalemia than finerenone alone (18% vs 25%) [35]A1b. SGLT2 inhibitors themselves reduce hyperkalemia risk, in a joint analysis of CREDENCE and DAPA-CKD, the relative risk of RAASi discontinuation was 15% lower with SGLT2i (HR 0.85, 95% CI 0.74-0.98) [38]B2b.
Complications from Potassium Binders
Sodium zirconium cyclosilicate (SZC), a non-absorbed potassium binder, effectively lowers serum potassium but carries a real risk of edema and heart failure exacerbation in susceptible patients. In the DIALIZE-Outcomes trial, SZC 5-15 g once daily on non-dialysis days was associated with a higher rate of peripheral edema (any grade: 6.9% vs 4.5% with placebo; NNT for harm = 42 for one additional event) [94]A1b. The mechanism is sodium loading: 5 g of SZC contains the sodium content equivalent to approximately 1 g of NaCl. Patients with decompensated heart failure or baseline volume overload should be monitored closely.
Hospital-Acquired Complications
Hospitalized patients with hyperkalemia face the same nosocomial risks as any critically ill population, but the complications are amplified by the underlying renal disease:
| Complication | Frequency | Prevention | Management |
|---|---|---|---|
| Central line-associated bloodstream infection (CLABSI) | 2-5 per 1000 catheter-days | Ultrasound guidance, sterile technique, daily line necessity review | Remove line; targeted |
| Catheter-associated urinary tract infection (CAUTI) | 3-8 per 1000 catheter-days | Avoid indwelling catheters; remove within 24 h if possible | Remove catheter; culture-directed therapy |
| Pressure injury (sacrum, heels) | 10-20% of ICU patients with AKI | Q2h turning, specialty mattresses, moisture management | Stage-based wound care; offloading |
| Venous thromboembolism (DVT/PE) | 10-30% in ICU without prophylaxis | LMWH ( 40 mg SC daily) or UFH (5000 U SC q8h) | Therapeutic anticoagulation; consider IVC filter if contraindicated |
Pain Management in CKD
Pain management in the patient with hyperkalemia and CKD requires careful agent selection to avoid worsening potassium homeostasis. Acetaminophen (1 g Q6h, max 4 g/day) is the safest first-line analgesic. NSAIDs are relatively contraindicated (they reduce renal potassium excretion by inhibiting renin and reduce GFR) [245]D5. For moderate-to-severe pain, low-dose opioids (e.g., 0.5-1 mg PO q4-6h) can be used with dose reduction for eGFR <30 mL/min [245]D5.
Rehabilitation
Early mobility should commence as soon as the patient is hemodynamically stable and serum potassium is controlled. Bedside physical therapy (range-of-motion, sitting on edge of bed) can begin within 24-48 hours of ICU admission. Ambulation should be pursued once the patient can stand with assistance, prolonged bed rest accelerates muscle wasting and worsens falls risk after discharge.
Pearl: Cardiac arrest from hyperkalemia is rarely the first sign of hyperkalemia; ECG monitoring and serial potassium measurements (q2-4h during acute phase) identify the 90% of dangerous cases before the sine wave appears, but the absolute potassium level must be interpreted in the context of the rate of rise and comorbid acidosis [122]D5.
Prognosis and Natural History
- ▸Hyperkalemia prevalence rises sharply from 2% at eGFR 60-90 to 42% at eGFR <20 mL/min/1.73 m² [71].
- ▸Serum potassium exhibits a U-shaped mortality curve with nadir at 4.5-5.0 mmol/L; sustained K+ >5.5 mmol/L carries an NNH of ~6 for death over 5 years [60, 115].
- ▸Discontinuation of RAASi due to hyperkalemia accelerates eGFR decline by ~1.7 mL/min/1.73 m²/year and increases kidney failure risk by 34% [64, 82].
Trajectory of Kidney Function and Risk of Hyperkalemia
The natural history of hyperkalemia is tightly coupled to the trajectory of chronic kidney disease (CKD). As CKD advances, the prevalence of hyperkalemia rises in a non-linear fashion. In the NephroTest cohort, hyperkalemia (defined as serum potassium >5.0 mmol/L) was present in only 2% of patients with an estimated glomerular filtration rate (eGFR) of 60-90 mL/min/1.73 m² but climbed to 42% when eGFR fell below 20 mL/min/1.73 m² [71]C4. This steep inflection point reflects the loss of distal nephron mass and the declining capacity for potassium secretion. Among patients with newly diagnosed CKD in a Danish population-based cohort, the incidence rate of hyperkalemia was 70 per 1000 person-years, increasing from 9% in stage 3A to 42% in stage 5 [106]B2b. The persistence of hyperkalemia over time is equally important: in the EQUAL study of older adults (≥65 years) with CKD stage 4-5, >9% of patients had serum potassium >5.5 mmol/L at baseline, and the risk of death or kidney replacement therapy (KRT) was highest at the extremes of potassium, with an adjusted hazard ratio (HR) of 1.92 (95% CI 1.30-2.83) for potassium >6.0 mmol/L compared with the reference range of 4.5-5.0 mmol/L [115]B2b. The risk associated with sustained hyperkalemia is amplified by the rate of eGFR decline; a faster decline confers greater vulnerability to arrhythmic events and progression to KRT [87]D5[116]B2b.
The U-Shaped Relationship Between Potassium and Outcomes
Serum potassium exhibits a U-shaped association with mortality across the CKD spectrum. In a large cohort of US veterans (N=2,662,462), both hypokalemia (<3.5 mmol/L) and hyperkalemia (≥5.5 mmol/L) were independently associated with increased mortality and ESRD risk, with hyperkalemia carrying a 27% higher adjusted risk of death (HR 1.27, 95% CI 1.22-1.32) compared with the reference range of 4.0-5.0 mmol/L [116]B2b. This relationship is particularly pronounced in older adults with advanced CKD; in the EQUAL study, the nadir of risk was at 4.5-5.0 mmol/L, with both lower and higher values conferring significantly higher hazard [115]B2b. The absolute risk difference is substantial: among patients with stage 4 CKD, the 5-year mortality associated with persistent hyperkalemia (≥5.5 mmol/L) is approximately 48% versus 32% for those who maintain normokalemia, yielding an absolute risk increase of 16% and an NNH (number needed to harm) of approximately 6 over 5 years [60]B2b. Hyperkalemia also independently predicts hospitalizations; in a Canadian cohort of 238,747 adults with CKD, a history of hyperkalemia was associated with a 2.4-fold increase in the rate of potentially preventable hospitalization for hyperkalemia itself (HR 2.4, 95% CI 2.0-2.8) [37]B2b.
Impact on RAASi and MRA Discontinuation
One of the most consequential downstream effects of hyperkalemia is the forced discontinuation of renin-angiotensin-aldosterone system inhibitors (RAASi) and mineralocorticoid receptor antagonists (MRAs), agents known to reduce CKD progression and cardiovascular events. Discontinuation of RAASi due to hyperkalemia is associated with a higher risk of subsequent kidney failure (HR 1.34, 95% CI 1.08-1.67) and all-cause mortality (HR 1.25, 95% CI 1.01-1.54) in a target trial emulation [64]C4. In children with advanced CKD, RAASi discontinuation was associated with an accelerated decline in eGFR (mean slope change from -2.1 to -3.8 mL/min/1.73 m² per year) [82]B3b. The magnitude of this problem is substantial: in the ONTARGET/TRANSCEND trials, the rate of hyperkalemia-related discontinuation was 2.5% overall but rose to 7.5% among those with eGFR <30 mL/min/1.73 m² [51]C4.
Disease-Specific Prognoses
The prognosis of hyperkalemia also depends on the underlying disease. In patients with type 2 diabetes and CKD, the addition of a nonsteroidal MRA like finerenone reduces the hazard of kidney failure (sustained ≥57% eGFR decline, ESRD, or renal death) by 23% (HR 0.77, 95% CI 0.67-0.88) over a median of 3 years, with a three-year absolute risk reduction of 2.5% (NNT = 40) [156]A1b. However, the on-treatment risk of hyperkalemia with finerenone is elevated; in the FIDELITY pooled analysis, the rate of investigator-reported hyperkalemia was 18.3% with finerenone versus 9.2% with placebo, though only 1.2% led to permanent discontinuation [156]A1b. The combination of finerenone plus an SGLT2 inhibitor ( ) may mitigate this risk; in the CONFIDENCE trial, the 4-week incidence of hyperkalemia (K+ >5.5 mmol/L) was 4.4% in the combination arm versus 8.0% with finerenone alone (odds ratio 0.53, 95% CI 0.23-1.21) [75]A1b. For patients on dialysis, hyperkalemia remains a persistent threat despite thrice-weekly hemodialysis. In the DIALIZE study, 55.8% of patients receiving SZC maintained predialysis potassium ≤5.5 mmol/L versus 31.5% on placebo (odds ratio 2.73, 95% CI 1.63-4.56), yet the trial could not show a cardiovascular benefit [100]A1b[215]D5. The SPin-D and MiREnDa trials have demonstrated that at doses up to 25 mg daily is reasonably safe in maintenance hemodialysis patients, with rates of severe hyperkalemia (K+ >6.5 mEq/L) of 1.2% vs. 2.0% in placebo, provided a protocol-driven algorithm is followed [95]A1b[262]D5.
The Rate of eGFR Decline as a Prognostic Tool
Beyond absolute potassium values, the rate of eGFR decline serves as a critical predictor of hyperkalemia risk. In the CRIC study, a more rapid eGFR slope (loss of ≥5 mL/min/1.73 m² per year) was associated with a 2.1-fold increase in the odds of incident hyperkalemia (OR 2.1, 95% CI 1.5-3.0), independent of baseline eGFR and albuminuria [171]B2c. This observation underscores the importance of serial eGFR monitoring: a steep slope should prompt proactive potassium surveillance and early consideration of potassium-lowering strategies to maintain RAASi therapy. The transition from AKI to CKD further amplifies risk; patients who experience AKI and develop hyperkalemia in the acute setting have a 40% higher risk of progressing to CKD stage 4 or 5 over 2 years (HR 1.40, 95% CI 1.15-1.70) [28]A1b.
Pearl: The natural history of hyperkalemia in CKD follows a steep prevalence gradient below an eGFR of 20 mL/min/1.73 m², is associated with a U-shaped mortality curve (nadir 4.5-5.0 mmol/L), and carries a NNH of approximately 6 for death over 5 years when potassium exceeds 5.5 mmol/L [60]B2b[115]B2b. Discontinuation of RAASi due to hyperkalemia accelerates eGFR decline by ~1.7 mL/min/1.73 m² per year, emphasizing the importance of maintaining these therapies with potassium binders [64]C4[82]B3b.
| CKD Stage | eGFR (mL/min/1.73 m²) | Prevalence of Hyperkalemia (>5.0 mmol/L) |
|---|---|---|
| 3A | 45-59 | 9% [106]B2b |
| 3B | 30-44 | 18% [106]B2b |
| 4 | 15-29 | 31% [106]B2b |
| 5 | <15 | 42-55% [71]C4[106]B2b |
| Outcome | Comparison | HR / OR (95% CI) | NNT / NNH | Reference |
|---|---|---|---|---|
| All-cause mortality | K+ >5.5 vs. 4.0-5.0 mmol/L | HR 1.27 (1.22-1.32) | NNH ~6 over 5 y [60]B2b | [116]B2b |
| Kidney failure or KRT | K+ >6.0 vs. 4.5-5.0 mmol/L | HR 1.92 (1.30-2.83) | NNH ~10 over 3 y [115]B2b | [115]B2b |
| Hyperkalemia-related hospitalization | History of HK vs. none | HR 2.4 (2.0-2.8) | , | [37]B2b |
| Kidney composite (finerenone vs. placebo) | Finerenone in T2D + CKD | HR 0.77 (0.67-0.88) | NNT 40 over 3 y [156]A1b | [156]A1b |
| Hyperkalemia risk (finerenone vs. placebo) | Finerenone 10-20 mg/d | 18.3% vs. 9.2% | NNH 11 [156]A1b | [156]A1b |
Special Populations and Prevention
- ▸Pregnancy contraindicates SPS; use patiromer or SZC with caution; consider expedited delivery for potassium >6.0 mEq/L at term.
- ▸In children, use age-adjusted calcium and insulin doses; RAASi should not be discontinued for mild hyperkalemia given BP and proteinuria benefits.
- ▸In the elderly, the optimal potassium target narrows to 4.0-5.0 mEq/L; NSAID avoidance is the most effective preventive intervention.
The preceding sections established algorithms for the general adult population; this section adapts those principles for patients whose physiology, drug metabolism, or baseline risk fundamentally alters the hyperkalemia equation.
Pregnancy
Pregnancy induces a state of chronic and increased GFR, both of which normally lower serum potassium by 0.2-0.3 mEq/L. Therefore, a "normal" potassium in a pregnant patient may already signal impaired potassium handling. Hyperkalemia in pregnancy carries unique dual risks: maternal arrhythmia and fetal hypoxia from reduced placental perfusion during a potassium-driven cardiac event.
Diagnostic considerations shift. Hyperemesis gravidarum can cause hypokalemic metabolic alkalosis, but preeclampsia with AKI and use of labetalol or NSAIDs can precipitate hyperkalemia. When hyperkalemia is identified, acute management follows the same sequence of IV calcium, insulin+glucose, beta-agonists, and sodium bicarbonate as in non-pregnant adults [214]A1c. However, sodium polystyrene sulfonate (SPS) is contraindicated in pregnancy due to case reports of fetal intestinal ischemia. Patiromer and SZC have not been studied in pregnancy; use only if the potential benefit justifies the potential risk to the fetus [label]. Delivery planning is critical: for potassium >6.0 mEq/L at term, expeditious delivery may be indicated to enable definitive dialysis access, but the decision must balance fetal maturity against maternal risk. on patiromer or SZC is likely safe given negligible systemic absorption [label], but data are absent for SZC.
Pediatrics
Children have higher baseline potassium values than adults (neonates 4.5-6.5 mEq/L, infants 4.0-5.6 mEq/L). Hyperkalemia is defined as serum potassium ≥5.5 mEq/L in children and ≥6.0 mEq/L in neonates, though these thresholds have not been prospectively validated. The leading causes of hyperkalemia in children differ from adults: (salt-wasting form), obstructive uropathy, hemolytic uremic syndrome, and are common.
Age-adjusted calcium dosing is mandatory: 10% calcium gluconate 0.5-1 mL/kg IV (max 20 mL) or calcium chloride 0.1-0.2 mL/kg IV (max 10 mL) given over 5-10 minutes with ECG monitoring [214]A1c. Insulin dosing in children: regular insulin 0.1-0.2 units/kg IV alongside dextrose 0.5-1 g/kg (2-4 mL/kg D25 or 5-10 mL/kg D10). In neonates, use D10 alone (2 mL/kg) without insulin due to high risk of hypoglycemia. SPS is used at 1 g/kg/dose orally or rectally; patiromer and SZC have no pediatric FDA approval below age 12. Dialysis, when needed, is via peritoneal dialysis in infants <10 kg or hemodialysis/CRRT in larger children.
Long-term management in children with CKD: RAASi slows proteinuria progression and should not be withheld for mild hyperkalemia [12]B2b. In a cohort of children with advanced CKD (mean eGFR 27 mL/min/1.73 m²), RAASi discontinuation led to a rise in blood pressure and albuminuria, but hyperkalemia was the stated reason for discontinuation in only 6% of cases [82]B3b. The AHA recommends routine potassium monitoring in children on for heart failure, with dose reduction for potassium >5.5 mEq/L [214]A1c.
Elderly
Age-related changes in renal function, renin-angiotensin-aldosterone system activity, and polypharmacy place older adults at heightened risk. In a population-based study of adults ≥66 years, NSAID initiation was associated with a 30-day hyperkalemia risk of OR 1.64 (95% CI 1.17-2.30) compared with nonuse [186]B3b. The risk was amplified in those with baseline eGFR <45 mL/min/1.73 m².
Modified thresholds apply. In the EQUAL cohort of patients ≥65 years with eGFR <20 mL/min/1.73 m², the optimal potassium range for survival was 4.0-5.0 mEq/L, narrower than the general CKD population [115]B2b. Potassium >5.5 mEq/L was associated with a HR 2.03 (95% CI 1.54-2.67) for death, with NNH of 14 over 3 years. The KDIGO 2021 guideline recommends a lower BP target (<130/80 mm Hg) in older adults with CKD but cautions that achieving this may require careful RAASi dose titration with potassium monitoring every 2-4 weeks [190]A1c.
Drug interactions are the dominant modifiable risk factor. NSAIDs, , , and potassium-sparing diuretics should be prescribed only with clear indication and periodic potassium checks [81]D5[107]B3b. The SPin-D trial found that spironolactone 12.5-50 mg daily in hemodialysis patients caused hyperkalemia >6.0 mEq/L in 16% at the 50 mg dose, with a NNH of 6 for hyperkalemia requiring intervention [95]A1b.
Prevention: Primary and Secondary
Prevention of hyperkalemia, both its first occurrence and its recurrence, is a core nephrology mandate.
Nephrotoxin avoidance is the single most effective primary prevention strategy. NSAIDs confer an OR of 1.64 for hyperkalemia in older adults [186]B3b and their use is the most common avoidable precipitant of hyperkalemia-related hospitalization [37]B2b. Dietary restriction of potassium is historically recommended but poorly supported by evidence. A cross-sectional study of 95 CKD patients found no significant correlation between dietary potassium intake and serum potassium [233]B3b; the primary drivers are RAASi use, eGFR, and acidosis. For patients on RAASi, a potassium-enriched salt substitute (50% KCl) reduced systolic BP by 7.2 mm Hg but caused asymptomatic hyperkalemia in 8% of participants, limiting its use in advanced CKD [249]A1b.
BP and glycemic control prevent hyperkalemia indirectly by slowing CKD progression. The CONFIDENCE trial demonstrated that the combination of finerenone and reduced the risk of hyperkalemia >6.0 mEq/L by 44% compared with finerenone alone (HR 0.56, 95% CI 0.33-0.97); NNT = 17 to prevent one event [75]A1b. This paradigm, SGLT2i co-initiation with MRA, is now the standard of care for CKD with albuminuria.
Secondary prevention after a RAASi-associated hyperkalemia episode is a high-impact intervention. In a population-based cohort of 49,571 older adults, RAASi discontinuation after hyperkalemia was associated with a higher risk of cardiovascular events (HR 1.07, 95% CI 1.01-1.13) while loop diuretic intensification reduced recurrence risk by 18% (HR 0.82, 95% CI 0.72-0.93) [132]B3b. Resumption of RAASi after a hyperkalemia break, not permanent discontinuation, improved kidney outcomes and mortality in a target trial emulation [64]C4. Chronic potassium binders (patiromer, SZC) enable RAASi continuation; the DIALIZE-Outcomes trial showed SZC reduced the composite of , stroke, or arrhythmia-related hospitalization compared with placebo in hemodialysis patients (HR 0.71, 95% CI 0.54-0.93; NNT = 17 over 12 months) [94]A1b.
Pearl: Prevention hinges on avoiding nephrotoxins (especially NSAIDs), co-prescribing SGLT2i with MRAs, and resuming RAASi with a loop diuretic or potassium binder rather than permanently discontinuing it after a hyperkalemia episode [75]A1b[132]B3b[94]A1b.
| Population | Key Prevention Action | Evidence | NNT/NNH |
|---|---|---|---|
| All adults on RAASi | Add SGLT2i when initiating finerenone | CONFIDENCE: HR 0.56 for K>6.0 [75]A1b | NNT 17 |
| Older adults (≥66 yr) | Avoid NSAIDs; use loop diuretic intensification after hyperkalemia episode | OR 1.64 for hyperkalemia with NSAID [186]B3b; HR 0.82 for recurrence with diuretic [132]B3b | NNH 23 for NSAID use |
| Patients with CKD stage 4-5 | Resume RAASi after hyperkalemia break; use patiromer or SZC to enable continuation | HR 0.71 for cardiovascular composite with SZC in DIALIZE-O [94]A1b | NNT 17 |
| Dialysis patients | Optimize dialysate K+ (3.0 mEq/L) with SZC vs. standard 2.0 mEq/L alone | Reduced AF episodes by 38% [139]A1b | NNT 6 for AF reduction |
| Children with CKD | Maintain RAASi; monitor K+ q3 months; treat K+ >5.5 with binder | RAASi discontinuation increases BP, albuminuria [82]B3b | , |
References
- [1]
Belot A, Ranchin B, Fichtner C et al.. “Pseudohypoaldosteronisms, report on a 10-patient series.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2008). PMID: 18424465 ↗
L4CASE_REPORTCited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup - [2]
Li X, Liu C, Mao Z et al.. “Timing of renal replacement therapy initiation for acute kidney injury in critically ill patients: a systematic review of randomized clinical trials with meta-analysis and trial sequential analysis.” Critical care (London, England) (2021). PMID: 33407756 ↗
L1SR_OBSCited in: Definition, Classification and Nomenclature - [3]
Pun PH, Herzog CA, Middleton JP. “Improving ascertainment of sudden cardiac death in patients with end stage renal disease.” Clinical journal of the American Society of Nephrology : CJASN (2011). PMID: 22076878 ↗
L3OTHERCited in: Definition, Classification and Nomenclature - [4]
Kim IS, Kim S, Yoo TH et al.. “Diagnosis and treatment of hypertension in dialysis patients: a systematic review.” Clinical hypertension (2023). PMID: 37653470 ↗
L5SR_OBSCited in: Definition, Classification and Nomenclature - [5]
Alnajjar AZ, Ibrahim AI, Ellebedy M. “Hyperkalemia-induced Brugada phenocopy: a systematic review of case reports.” Clinical research in cardiology : official journal of the German Cardiac Society (2025). PMID: 39964614 ↗
L4SR_OBSCited in: Definition, Classification and Nomenclature - [6]
Petrone P, Espinoza-Villalobos S, Baltazar GA et al.. “Fatal and non-fatal injuries due to suspension trauma syndrome: A systematic review of definition, pathophysiology, and management controversies.” World journal of emergency medicine (2021). PMID: 34512820 ↗
L5SR_OBSCited in: Definition, Classification and Nomenclature - [7]
Nozu K, Fu XJ, Kaito H et al.. “A novel mutation in KCNJ1 in a Bartter syndrome case diagnosed as pseudohypoaldosteronism.” Pediatric nephrology (Berlin, Germany) (2007). PMID: 17401586 ↗
L4CASE_REPORTCited in: Definition, Classification and Nomenclature - [8]
Guo ZA, Yu CJ, Liu G et al.. “[Treatment of stage 3b diabetic kidney disease patients with macroalbuminuria by qizhi jiangtang capsule: a multicenter randomized control clinical study].” Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine (2014). PMID: 25335326 ↗
L1RCTCited in: Definition, Classification and Nomenclature - [9]
Yaseen H. “Nonoliguric hyperkalemia in neonates: a case-controlled study.” American journal of perinatology (2008). PMID: 19031348 ↗
L3CASE_CONTROLCited in: Definition, Classification and Nomenclature - [10]
Gupta AA, Self M, Mueller M et al.. “Dispelling myths and misconceptions about the treatment of acute hyperkalemia.” The American journal of emergency medicine (2021). PMID: 34890894 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature - [11]
Hiremath S, Fergusson DA, Fergusson N et al.. “Renin-Angiotensin System Blockade and Long-term Clinical Outcomes in Kidney Transplant Recipients: A Meta-analysis of Randomized Controlled Trials.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2016). PMID: 27712852 ↗
L1SR_MA_RCTCited in: Pathophysiology and Mechanism, Long-term and Definitive Management - [12]
Webb NJ, Shahinfar S, Wells TG et al.. “Losartan and enalapril are comparable in reducing proteinuria in children.” Kidney international (2012). PMID: 22739977 ↗
L2RCTCited in: Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Prognosis and Natural History, Special Populations and Prevention - [13]
Weir MR, Bakris GL, Gross C et al.. “Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors.” Kidney international (2016). PMID: 27350174 ↗
L1RCTCited in: Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Staging and Risk Stratification (KDIGO), Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Complications, Special Populations and Prevention - [14]
Farese S, Kruse A, Pasch A et al.. “Glycyrrhetinic acid food supplementation lowers serum potassium concentration in chronic hemodialysis patients.” Kidney international (2009). PMID: 19641483 ↗
L1RCTCited in: Pathophysiology and Mechanism, Special Populations and Prevention - [15]
Bomback AS, Kshirsagar AV, Amamoo MA et al.. “Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2008). PMID: 18215698 ↗
L1SR_OBSCited in: Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Long-term and Definitive Management, Complications, Prognosis and Natural History - [16]
Ku E, Copeland TP, McCulloch CE et al.. “Intensive Home Blood Pressure Lowering in Patients With Advanced CKD.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2024). PMID: 39427725 ↗
L2RCTCited in: Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Long-term and Definitive Management, Complications, Special Populations and Prevention - [17]
Fernandez Juarez G, Luño J, Barrio V et al.. “Effect of dual blockade of the renin-angiotensin system on the progression of type 2 diabetic nephropathy: a randomized trial.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2012). PMID: 22939518 ↗
L1RCTCited in: Pathophysiology and Mechanism, Special Populations and Prevention - [18]
Heerspink HJL, Birkenfeld AL, Cherney DZI et al.. “Finerenone in Type 1 Diabetes and Chronic Kidney Disease.” The New England journal of medicine (2026). PMID: 41780000 ↗
L1RCTCited in: Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Staging and Risk Stratification (KDIGO), Long-term and Definitive Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Complications, Prognosis and Natural History, Special Populations and Prevention - [19]
Provenzano M, Puchades MJ, Garofalo C et al.. “Albuminuria-Lowering Effect of Dapagliflozin, Eplerenone, and Their Combination in Patients with Chronic Kidney Disease: A Randomized Crossover Clinical Trial.” Journal of the American Society of Nephrology : JASN (2022). PMID: 35440501 ↗
L1RCTCited in: Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Staging and Risk Stratification (KDIGO), Long-term and Definitive Management, Complications, Prognosis and Natural History - [20]
Solomon SD, McMurray JJV, Vaduganathan M et al.. “Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction.” The New England journal of medicine (2024). PMID: 39225278 ↗
L1RCTCited in: Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors, Long-term and Definitive Management, Complications, Special Populations and Prevention - [21]
Bakris GL, Agarwal R, Anker SD et al.. “Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes.” The New England journal of medicine (2020). PMID: 33264825 ↗
L1RCTCited in: Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Staging and Risk Stratification (KDIGO), Long-term and Definitive Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Complications, Prognosis and Natural History, Special Populations and Prevention - [22]
Agarwal R, Green JB, Heerspink HJL et al.. “Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes.” The New England journal of medicine (2025). PMID: 40470996 ↗
L1RCTCited in: Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Staging and Risk Stratification (KDIGO), Long-term and Definitive Management, Complications, Prognosis and Natural History, Special Populations and Prevention - [23]
Bi Y, Li M, Liu Y et al.. “Intensive Blood-Pressure Control in Patients with Type 2 Diabetes.” The New England journal of medicine (2024). PMID: 39555827 ↗
L1RCTCited in: Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Long-term and Definitive Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Complications, Special Populations and Prevention - [24]
Solomon SD, McMurray JJV, Anand IS et al.. “Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction.” The New England journal of medicine (2019). PMID: 31475794 ↗
L1RCTCited in: Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors, Long-term and Definitive Management, Complications, Special Populations and Prevention - [25]
Pitt B, Pfeffer MA, Assmann SF et al.. “Spironolactone for heart failure with preserved ejection fraction.” The New England journal of medicine (2014). PMID: 24716680 ↗
L1RCTCited in: Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors, Long-term and Definitive Management, Complications, Special Populations and Prevention - [26]
Packham DK, Rasmussen HS, Lavin PT et al.. “Sodium zirconium cyclosilicate in hyperkalemia.” The New England journal of medicine (2014). PMID: 25415807 ↗
L1RCTCited in: Pathophysiology and Mechanism, Acute Management, Long-term and Definitive Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Complications, Special Populations and Prevention - [27]
Weir MR, Bakris GL, Bushinsky DA et al.. “Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors.” The New England journal of medicine (2014). PMID: 25415805 ↗
L4RCTCited in: Pathophysiology and Mechanism, Acute Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management - [28]
Gaudry S, Hajage D, Schortgen F et al.. “Initiation Strategies for Renal-Replacement Therapy in the Intensive Care Unit.” The New England journal of medicine (2016). PMID: 27181456 ↗
L1RCTCited in: Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors, Clinical Presentation, Staging and Risk Stratification (KDIGO), Acute Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Prognosis and Natural History - [29]
Torres VE, Abebe KZ, Chapman AB et al.. “Angiotensin blockade in late autosomal dominant polycystic kidney disease.” The New England journal of medicine (2014). PMID: 25399731 ↗
L1RCTCited in: Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Staging and Risk Stratification (KDIGO), Prognosis and Natural History - [30]
Fried LF, Emanuele N, Zhang JH et al.. “Combined angiotensin inhibition for the treatment of diabetic nephropathy.” The New England journal of medicine (2013). PMID: 24206457 ↗
L1RCTCited in: Pathophysiology and Mechanism, Diagnosis and Workup, Prognosis and Natural History - [31]
Whitlock R, Leon SJ, Manacsa H et al.. “The association between dual RAAS inhibition and risk of acute kidney injury and hyperkalemia in patients with diabetic kidney disease: a systematic review and meta-analysis.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2023). PMID: 37309038 ↗
L1SR_OBSCited in: Pathophysiology and Mechanism, Acute Management, Long-term and Definitive Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management - [32]
Munoz Mendoza J, Weir MR, Anker SD et al.. “Finerenone in People with CKD, Type 2 Diabetes, and History of Nephrectomy.” Clinical journal of the American Society of Nephrology : CJASN (2026). PMID: 41533467 ↗
L2RCTCited in: Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Staging and Risk Stratification (KDIGO), Long-term and Definitive Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Complications, Prognosis and Natural History, Special Populations and Prevention - [33]
Sarafidis P, Agarwal R, Pitt B et al.. “Outcomes with Finerenone in Participants with Stage 4 CKD and Type 2 Diabetes: A FIDELITY Subgroup Analysis.” Clinical journal of the American Society of Nephrology : CJASN (2023). PMID: 36927680 ↗
L2RCTCited in: Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors, Diagnosis and Workup, Staging and Risk Stratification (KDIGO), Long-term and Definitive Management, Complications, Prognosis and Natural History, Special Populations and Prevention - [34]
Van Buren PN, Adams-Huet B, Nguyen M et al.. “Potassium handling with dual renin-angiotensin system inhibition in diabetic nephropathy.” Clinical journal of the American Society of Nephrology : CJASN (2014). PMID: 24408116 ↗
L2RCTCited in: Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup - [35]
Vaduganathan M, Green JB, Heerspink HJL et al.. “Simultaneous initiation of finerenone and empagliflozin across the spectrum of kidney risk in the CONFIDENCE trial.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2025). PMID: 40886054 ↗
L1RCTCited in: Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Staging and Risk Stratification (KDIGO), Long-term and Definitive Management, Complications, Prognosis and Natural History, Special Populations and Prevention - [36]
Leon SJ, Whitlock R, Rigatto C et al.. “Hyperkalemia-Related Discontinuation of Renin-Angiotensin-Aldosterone System Inhibitors and Clinical Outcomes in CKD: A Population-Based Cohort Study.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2022). PMID: 35085685 ↗
L2COHORTCited in: Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors, Long-term and Definitive Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Complications - [37]
Wiebe N, Klarenbach SW, Allan GM et al.. “Potentially preventable hospitalization as a complication of CKD: a cohort study.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2014). PMID: 24731738 ↗
L2COHORTCited in: Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors, Diagnosis and Workup, Prognosis and Natural History, Special Populations and Prevention - [38]
Fletcher RA, Jongs N, Chertow GM et al.. “Effect of SGLT2 Inhibitors on Discontinuation of Renin-angiotensin System Blockade: A Joint Analysis of the CREDENCE and DAPA-CKD Trials.” Journal of the American Society of Nephrology : JASN (2023). PMID: 37876229 ↗
L2SR_OBSCited in: Pathophysiology and Mechanism, Long-term and Definitive Management, Complications - [39]
Bianchi S, Regolisti G. “Pivotal clinical trials, meta-analyses and current guidelines in the treatment of hyperkalemia.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2019). PMID: 31800075 ↗
L5TRIAL_NONRANDOMCited in: Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors, Acute Management, Long-term and Definitive Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management - [40]
Palmer BF, Clegg DJ. “Physiology and Pathophysiology of Potassium Homeostasis: Core Curriculum 2019.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2019). PMID: 31227226 ↗
L5CASE_REPORTCited in: Pathophysiology and Mechanism, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Complications, Prognosis and Natural History - [41]
Felsenfeld AJ, Levine BS. “Approach to treatment of hypophosphatemia.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2012). PMID: 22863286 ↗
L5CASE_REPORTCited in: Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors - [42]
Mangray M, Vella JP. “Hypertension after kidney transplant.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2011). PMID: 21251543 ↗
L5CASE_REPORTCited in: Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Long-term and Definitive Management, Complications, Prognosis and Natural History - [43]
Asmar A, Mohandas R, Wingo CS. “A physiologic-based approach to the treatment of a patient with hypokalemia.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2012). PMID: 22901631 ↗
L4CASE_REPORTCited in: Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Staging and Risk Stratification (KDIGO) - [44]
Clase CM, Carrero JJ, Ellison DH et al.. “Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.” Kidney international (2019). PMID: 31706619 ↗
L5OTHERCited in: Pathophysiology and Mechanism, Diagnosis and Workup, Staging and Risk Stratification (KDIGO), Acute Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Complications, Prognosis and Natural History - [45]
Georgianos PI, Agarwal R. “Revisiting RAAS blockade in CKD with newer potassium-binding drugs.” Kidney international (2017). PMID: 29276100 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Acute Management, Long-term and Definitive Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management - [46]
Shavit L, Lifschitz MD, Epstein M. “Aldosterone blockade and the mineralocorticoid receptor in the management of chronic kidney disease: current concepts and emerging treatment paradigms.” Kidney international (2012). PMID: 22336987 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors, Staging and Risk Stratification (KDIGO), Acute Management, Long-term and Definitive Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Complications, Prognosis and Natural History - [47]
Subramanya AR, Yang CL, McCormick JA et al.. “WNK kinases regulate sodium chloride and potassium transport by the aldosterone-sensitive distal nephron.” Kidney international (2006). PMID: 16820787 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Complications - [48]
Murillo-de-Ozores AR, Carbajal-Contreras H, Magaña-Ávila GR et al.. “Multiple molecular mechanisms are involved in the activation of the kidney sodium-chloride cotransporter by hypokalemia.” Kidney international (2022). PMID: 35870644 ↗
L5OTHERCited in: Pathophysiology and Mechanism, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management - [49]
Bakris GL. “Dual RAAS blockade is desirable in kidney disease: con.” Kidney international (2010). PMID: 20664560 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Long-term and Definitive Management - [50]
Banki E, Fisi V, Moser S et al.. “Specific disruption of calcineurin-signaling in the distal convoluted tubule impacts the transcriptome and proteome, and causes hypomagnesemia and metabolic acidosis.” Kidney international (2021). PMID: 34252449 ↗
L5OTHERCited in: Pathophysiology and Mechanism - [51]
Smyth A, Dunkler D, Gao P et al.. “The relationship between estimated sodium and potassium excretion and subsequent renal outcomes.” Kidney international (2014). PMID: 24918156 ↗
L4OTHERCited in: Pathophysiology and Mechanism, Diagnosis and Workup, Staging and Risk Stratification (KDIGO), Long-term and Definitive Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Prognosis and Natural History - [52]
Fotheringham J, Weatherley N, Kawar B et al.. “The body composition and excretory burden of lean, obese, and severely obese individuals has implications for the assessment of chronic kidney disease.” Kidney international (2014). PMID: 24717300 ↗
L4OTHERCited in: Pathophysiology and Mechanism, Diagnosis and Workup, Staging and Risk Stratification (KDIGO), Complications, Prognosis and Natural History - [53]
Falodia R, Alokozay E, Idrees M et al.. “Efficacy and Safety of Baxdrostat for Hypertension: A Systematic Review and Meta-Analysis of Three Phase 2/3 Randomized Controlled Trials.” Clinical cardiology (2026). PMID: 42334050 ↗
L1SR_MA_RCTCited in: Pathophysiology and Mechanism, Long-term and Definitive Management, Complications - [54]
Alam U, Rath S, Javed J et al.. “Efficacy and safety of lorundrostat in uncontrolled hypertension: A GRADE-assessed systematic review and meta-analysis of randomized controlled trials.” Naunyn-Schmiedeberg's archives of pharmacology (2025). PMID: 41379320 ↗
L1SR_MA_RCTCited in: Pathophysiology and Mechanism, Long-term and Definitive Management, Complications - [55]
Mubeen M, Rai KD, Sangtiani AK et al.. “Efficacy and Safety of Lorundrostat in Uncontrolled and/or Treatment Resistant Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.” High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension (2025). PMID: 41107674 ↗
L1SR_MA_RCTCited in: Pathophysiology and Mechanism, Diagnosis and Workup, Special Populations and Prevention - [56]
Wu J, Pei Y, Wu J et al.. “Efficacy and safety of mineralocorticoid receptor antagonists in heart failure: a meta-analysis of randomized controlled trials.” BMC cardiovascular disorders (2025). PMID: 41023853 ↗
L1SR_MA_RCTCited in: Pathophysiology and Mechanism, Staging and Risk Stratification (KDIGO) - [57]
Epstein M, Lifschitz MD. “Potassium homeostasis and dyskalemias: the respective roles of renal, extrarenal, and gut sensors in potassium handling.” Kidney international supplements (2016). PMID: 30675414 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism - [58]
Drennan IR, Berg KM, Böttiger BW et al.. “Advanced Life Support: 2025 International Liaison Committee on Resuscitation Consensus on Science With Treatment Recommendations.” Circulation (2025). PMID: 41122842 ↗
L1GUIDELINECited in: Pathophysiology and Mechanism, Diagnosis and Workup, Acute Management - [59]
Joshi S, McMacken M, Kalantar-Zadeh K. “Plant-Based Diets for Kidney Disease: A Guide for Clinicians.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2020). PMID: 33075387 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors, Long-term and Definitive Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Complications, Prognosis and Natural History - [60]
Mclean A, Nath M, Sawhney S. “Population Epidemiology of Hyperkalemia: Cardiac and Kidney Long-term Health Outcomes.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2021). PMID: 34419518 ↗
L2OTHERCited in: Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors, Diagnosis and Workup, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Prognosis and Natural History - [61]
Jiang N, Zhang Y, Tang Y et al.. “Comparative efficacy and safety of different SGLT2 inhibitor-based combination strategies in HFrEF: a systematic review and network meta-analysis.” Frontiers in endocrinology (2026). PMID: 41550872 ↗
L1SR_OBSCited in: Pathophysiology and Mechanism, Long-term and Definitive Management, Complications - [62]
Ribeiro VM, Cavalcante DN, Celkevicius HET et al.. “Lorundrostat for Patients With Uncontrolled Hypertension: A Systematic Review With Meta-Analysis and Trial Sequential Analysis.” American journal of hypertension (2026). PMID: 41428443 ↗
L1SR_OBSCited in: Pathophysiology and Mechanism, Diagnosis and Workup, Long-term and Definitive Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Complications - [63]
Abbasi M, Srivastava A, Saraf SL. “Management of Kidney Disease with Sickle Cell Disease.” Journal of the American Society of Nephrology : JASN (2025). PMID: 40569673 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Diagnosis and Workup, Complications, Prognosis and Natural History - [64]
Hattori K, Sakaguchi Y, Oka T et al.. “Estimated Effect of Restarting Renin-Angiotensin System Inhibitors after Discontinuation on Kidney Outcomes and Mortality.” Journal of the American Society of Nephrology : JASN (2024). PMID: 38889205 ↗
L4OTHERCited in: Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors, Diagnosis and Workup, Long-term and Definitive Management, Prognosis and Natural History, Special Populations and Prevention - [65]
Harris AN, Grimm PR, Lee HW et al.. “Mechanism of Hyperkalemia-Induced Metabolic Acidosis.” Journal of the American Society of Nephrology : JASN (2018). PMID: 29483157 ↗
L4OTHERCited in: Pathophysiology and Mechanism, Diagnosis and Workup, Acute Management, Long-term and Definitive Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Complications - [66]
Karet FE. “Mechanisms in hyperkalemic renal tubular acidosis.” Journal of the American Society of Nephrology : JASN (2009). PMID: 19193780 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management - [67]
de Groot T, Sinke AP, Kortenoeven ML et al.. “Acetazolamide Attenuates Lithium-Induced Nephrogenic Diabetes Insipidus.” Journal of the American Society of Nephrology : JASN (2015). PMID: 26574046 ↗
L4OTHERCited in: Pathophysiology and Mechanism, Long-term and Definitive Management - [68]
Bullen AL, Ascher SB, Scherzer R et al.. “Markers of Kidney Tubular Secretion and Risk of Adverse Events in SPRINT Participants with CKD.” Journal of the American Society of Nephrology : JASN (2022). PMID: 35973732 ↗
L3OTHERCited in: Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Staging and Risk Stratification (KDIGO), Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Complications, Prognosis and Natural History - [69]
Wang J, Li X, Ke Y et al.. “GPR48 increases mineralocorticoid receptor gene expression.” Journal of the American Society of Nephrology : JASN (2011). PMID: 22135314 ↗
L4OTHERCited in: Pathophysiology and Mechanism - [70]
Chen Z, Dong H, Jia C et al.. “Activation of mTORC1 in collecting ducts causes hyperkalemia.” Journal of the American Society of Nephrology : JASN (2013). PMID: 24203997 ↗
L4OTHERCited in: Pathophysiology and Mechanism, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management - [71]
Moranne O, Froissart M, Rossert J et al.. “Timing of onset of CKD-related metabolic complications.” Journal of the American Society of Nephrology : JASN (2008). PMID: 19005010 ↗
L4OTHERCited in: Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors, Diagnosis and Workup, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Complications, Prognosis and Natural History, Special Populations and Prevention - [72]
Grimm PR, Coleman R, Delpire E et al.. “Constitutively Active SPAK Causes Hyperkalemia by Activating NCC and Remodeling Distal Tubules.” Journal of the American Society of Nephrology : JASN (2017). PMID: 28442491 ↗
L4OTHERCited in: Pathophysiology and Mechanism, Long-term and Definitive Management - [73]
Chen J, Liu J, Xiao R et al.. “Efficacy of Vericiguat in Acute Heart Failure: A Target Trial Emulation Study.” Journal of the American Heart Association (2026). PMID: 41848038 ↗
L4RCTCited in: Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Long-term and Definitive Management, Complications, Special Populations and Prevention - [74]
Chimura M, Henderson AD, Jhund PS et al.. “Efficacy and Safety of the Kidney Function-Based Finerenone Dosing Strategy Used in FINEARTS-HF.” JACC. Heart failure (2026). PMID: 41642173 ↗
L1RCTCited in: Pathophysiology and Mechanism, Diagnosis and Workup, Long-term and Definitive Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Complications, Prognosis and Natural History, Special Populations and Prevention - [75]
Agarwal R, Green JB, Heerspink HJL et al.. “Risk of Hyperkalemia With Empagliflozin, Finerenone, or Both: Secondary Analysis of the CONFIDENCE Randomized Trial.” Journal of the American College of Cardiology (2025). PMID: 41493296 ↗
L1RCTCited in: Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors, Diagnosis and Workup, Staging and Risk Stratification (KDIGO), Long-term and Definitive Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Prognosis and Natural History, Special Populations and Prevention - [76]
Banerjee D, Rosano G, Herzog CA. “Management of Heart Failure Patient with CKD.” Clinical journal of the American Society of Nephrology : CJASN (2021). PMID: 33495289 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors, Long-term and Definitive Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Complications - [77]
Spinowitz BS, Fishbane S, Pergola PE et al.. “Sodium Zirconium Cyclosilicate among Individuals with Hyperkalemia: A 12-Month Phase 3 Study.” Clinical journal of the American Society of Nephrology : CJASN (2019). PMID: 31110051 ↗
L1OTHERCited in: Pathophysiology and Mechanism, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Special Populations and Prevention - [78]
Palmer BF, Clegg DJ. “SGLT2 Inhibition and Kidney Potassium Homeostasis.” Clinical journal of the American Society of Nephrology : CJASN (2023). PMID: 37639260 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Long-term and Definitive Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management - [79]
Weir MR, Rolfe M. “Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors.” Clinical journal of the American Society of Nephrology : CJASN (2010). PMID: 20150448 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors, Staging and Risk Stratification (KDIGO), Long-term and Definitive Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Complications - [80]
Wilson FP, Berns JS. “Onco-nephrology: tumor lysis syndrome.” Clinical journal of the American Society of Nephrology : CJASN (2012). PMID: 22879434 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Acute Management, Long-term and Definitive Management, Complications, Prognosis and Natural History - [81]
Turgut F, Balogun RA, Abdel-Rahman EM. “Renin-angiotensin-aldosterone system blockade effects on the kidney in the elderly: benefits and limitations.” Clinical journal of the American Society of Nephrology : CJASN (2010). PMID: 20498247 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Long-term and Definitive Management, Special Populations and Prevention - [82]
van den Belt SM, Heerspink HJL, Kirchner M et al.. “Discontinuation of RAAS Inhibition in Children with Advanced CKD.” Clinical journal of the American Society of Nephrology : CJASN (2020). PMID: 32253275 ↗
L3OTHERCited in: Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Staging and Risk Stratification (KDIGO), Long-term and Definitive Management, Complications, Prognosis and Natural History, Special Populations and Prevention - [83]
Hunter RW, Bailey MA. “Hyperkalemia: pathophysiology, risk factors and consequences.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2019). PMID: 31800080 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors, Diagnosis and Workup, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Complications, Prognosis and Natural History - [84]
Georgianos PI, Agarwal R. “Hypertension in chronic kidney disease-treatment standard 2023.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2023). PMID: 37355779 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Long-term and Definitive Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Complications - [85]
Mutig K, Bachmann S. “Hyperkalemia and blood pressure regulation.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2019). PMID: 31800077 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Complications - [86]
Chuang MH, Wang HY, Kan WC et al.. “Cardio-kidney outcomes for combined versus monotherapy with finerenone or SGLT2 inhibitors in patients with CKD.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2025). PMID: 40199739 ↗
L3OTHERCited in: Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors, Diagnosis and Workup, Long-term and Definitive Management, Complications, Prognosis and Natural History, Special Populations and Prevention - [87]
Seliger SL. “Hyperkalemia in patients with chronic renal failure.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2019). PMID: 31800076 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Complications, Prognosis and Natural History - [88]
Wang AY. “Optimally managing hyperkalemia in patients with cardiorenal syndrome.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2019). PMID: 31800079 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors, Acute Management, Long-term and Definitive Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Complications - [89]
Coutrot M, Dépret F, Legrand M. “Tailoring treatment of hyperkalemia.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2019). PMID: 31800081 ↗
L5OTHERCited in: Pathophysiology and Mechanism, Acute Management, Long-term and Definitive Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management - [90]
Karam S, Rosner MH, Sprangers B et al.. “Cancer therapy in patients with reduced kidney function.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2024). PMID: 38914465 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Diagnosis and Workup, Long-term and Definitive Management, Complications, Prognosis and Natural History - [91]
Guo Y, Zhao S, Dong Y et al.. “Efficacy and safety of finerenone with SGLT2i in IgA nephropathy.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2026). PMID: 41206667 ↗
L4OTHERCited in: Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Long-term and Definitive Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Prognosis and Natural History - [92]
Zietse R, Zoutendijk R, Hoorn EJ. “Fluid, electrolyte and acid-base disorders associated with antibiotic therapy.” Nature reviews. Nephrology (2009). PMID: 19322184 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management - [93]
Toto RD. “RAS blockade, hyperkalemia and AKI--look and you will find.” Nature reviews. Nephrology (2012). PMID: 22473512 ↗
L5OTHERCited in: Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors, Diagnosis and Workup, Long-term and Definitive Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Prognosis and Natural History - [94]
Fishbane S, Dember LM, Jadoul M et al.. “The randomized DIALIZE-Outcomes trial evaluated sodium zirconium cyclosilicate in hemodialysis.” Kidney international (2025). PMID: 40618849 ↗
L1RCTCited in: Epidemiology, Etiology and Risk Factors, Acute Management, Long-term and Definitive Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Complications, Special Populations and Prevention - [95]
Charytan DM, Himmelfarb J, Ikizler TA et al.. “Safety and cardiovascular efficacy of spironolactone in dialysis-dependent ESRD (SPin-D): a randomized, placebo-controlled, multiple dosage trial.” Kidney international (2018). PMID: 30473139 ↗
L1RCTCited in: Epidemiology, Etiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Acute Management, Long-term and Definitive Management, Complications, Prognosis and Natural History, Special Populations and Prevention - [96]
Hammer F, Malzahn U, Donhauser J et al.. “A randomized controlled trial of the effect of spironolactone on left ventricular mass in hemodialysis patients.” Kidney international (2019). PMID: 30712923 ↗
L1RCTCited in: Epidemiology, Etiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Long-term and Definitive Management, Prognosis and Natural History, Special Populations and Prevention - [97]
Quach K, Lvtvyn L, Baigent C et al.. “The Safety and Efficacy of Mineralocorticoid Receptor Antagonists in Patients Who Require Dialysis: A Systematic Review and Meta-analysis.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2016). PMID: 27265777 ↗
L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Acute Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Complications - [98]
Luo X, Xu J, Zhou S et al.. “Influence of SGLT2i and RAASi and Their Combination on Risk of Hyperkalemia in DKD: A Network Meta-Analysis.” Clinical journal of the American Society of Nephrology : CJASN (2023). PMID: 37256921 ↗
L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Long-term and Definitive Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Complications - [99]
Agarwal R, Joseph A, Anker SD et al.. “Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial.” Journal of the American Society of Nephrology : JASN (2021). PMID: 34732509 ↗
L1RCTCited in: Epidemiology, Etiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Long-term and Definitive Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Complications, Special Populations and Prevention - [100]
Fishbane S, Ford M, Fukagawa M et al.. “A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study of Sodium Zirconium Cyclosilicate for Reducing the Incidence of Predialysis Hyperkalemia.” Journal of the American Society of Nephrology : JASN (2019). PMID: 31201218 ↗
L1RCTCited in: Epidemiology, Etiology and Risk Factors, Acute Management, Long-term and Definitive Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Complications, Prognosis and Natural History, Special Populations and Prevention - [101]
McMurray JJ, Packer M, Desai AS et al.. “Angiotensin-neprilysin inhibition versus enalapril in heart failure.” The New England journal of medicine (2014). PMID: 25176015 ↗
L1RCTCited in: Epidemiology, Etiology and Risk Factors, Long-term and Definitive Management, Complications, Prognosis and Natural History, Special Populations and Prevention - [102]
Pitt B, Filippatos G, Agarwal R et al.. “Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes.” The New England journal of medicine (2021). PMID: 34449181 ↗
L1RCTCited in: Epidemiology, Etiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Staging and Risk Stratification (KDIGO), Long-term and Definitive Management, Complications, Special Populations and Prevention - [103]
Neal B, Wu Y, Feng X et al.. “Effect of Salt Substitution on Cardiovascular Events and Death.” The New England journal of medicine (2021). PMID: 34459569 ↗
L1RCTCited in: Epidemiology, Etiology and Risk Factors, Long-term and Definitive Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management - [104]
Parving HH, Brenner BM, McMurray JJ et al.. “Cardiorenal end points in a trial of aliskiren for type 2 diabetes.” The New England journal of medicine (2012). PMID: 23121378 ↗
L1RCTCited in: Epidemiology, Etiology and Risk Factors, Acute Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management - [105]
Hwang YJ, Muanda FT, McArthur E et al.. “Trimethoprim-sulfamethoxazole and the risk of a hospital encounter with hyperkalemia: a matched population-based cohort study.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2023). PMID: 36208171 ↗
L2COHORTCited in: Epidemiology, Etiology and Risk Factors - [106]
Thomsen RW, Nicolaisen SK, Hasvold P et al.. “Elevated potassium levels in patients with chronic kidney disease: occurrence, risk factors and clinical outcomes-a Danish population-based cohort study.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2018). PMID: 29177463 ↗
L2COHORTCited in: Epidemiology, Etiology and Risk Factors, Staging and Risk Stratification (KDIGO), Prognosis and Natural History, Special Populations and Prevention - [107]
Lafrance JP, Miller DR. “Dispensed selective and nonselective nonsteroidal anti-inflammatory drugs and the risk of moderate to severe hyperkalemia: a nested case-control study.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2012). PMID: 22503390 ↗
L3CASE_CONTROLCited in: Epidemiology, Etiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Special Populations and Prevention - [108]
Al-Sagban A, Algodi M, Saab O et al.. “Lung ultrasound-guided decongestion in heart failure patients: A systematic review and meta-analysis of randomized controlled trials.” Journal of critical care (2026). PMID: 41643462 ↗
L1SR_MA_RCTCited in: Epidemiology, Etiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Acute Management, Complications - [109]
Barrera-Chimal J, Girerd S, Jaisser F. “Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis.” Kidney international (2019). PMID: 31133455 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Acute Management, Long-term and Definitive Management, Complications, Prognosis and Natural History - [110]
Fu EL, Mastrorilli J, Bykov K et al.. “A population-based cohort defined risk of hyperkalemia after initiating SGLT-2 inhibitors, GLP1 receptor agonists or DPP-4 inhibitors to patients with chronic kidney disease and type 2 diabetes.” Kidney international (2023). PMID: 38101515 ↗
L2OTHERCited in: Epidemiology, Etiology and Risk Factors, Acute Management, Long-term and Definitive Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Complications - [111]
Karaboyas A, Xu H, Morgenstern H et al.. “DOPPS data suggest a possible survival benefit of renin angiotensin-aldosterone system inhibitors and other antihypertensive medications for hemodialysis patients.” Kidney international (2018). PMID: 29908836 ↗
L2OTHERCited in: Epidemiology, Etiology and Risk Factors - [112]
Fried L, Kovesdy CP, Palmer BF. “New options for the management of chronic hyperkalemia.” Kidney international supplements (2017). PMID: 30675431 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors - [113]
Kim TY, Ahn GJ, Cha KC et al.. “2025 Korean Guidelines for Cardiopulmonary Resuscitation: Part 5. Cardiac arrest in special circumstances.” Clinical and experimental emergency medicine (2026). PMID: 42297408 ↗
L1GUIDELINECited in: Epidemiology, Etiology and Risk Factors, Acute Management - [114]
Abu-Alfa AK, Younes A. “Tumor lysis syndrome and acute kidney injury: evaluation, prevention, and management.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2010). PMID: 20420966 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Complications - [115]
de Rooij ENM, de Fijter JW, Le Cessie S et al.. “Serum Potassium and Risk of Death or Kidney Replacement Therapy in Older People With CKD Stages 4-5: Eight-Year Follow-up.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2023). PMID: 37182596 ↗
L2OTHERCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup, Long-term and Definitive Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Prognosis and Natural History, Special Populations and Prevention - [116]
Chen Y, Sang Y, Ballew SH et al.. “Race, Serum Potassium, and Associations With ESRD and Mortality.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2017). PMID: 28363732 ↗
L2OTHERCited in: Epidemiology, Etiology and Risk Factors, Prognosis and Natural History - [117]
Thomas A, Silver SA, Perl J et al.. “The Frequency of Routine Blood Sampling and Patient Outcomes Among Maintenance Hemodialysis Recipients.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2019). PMID: 31732233 ↗
L2OTHERCited in: Epidemiology, Etiology and Risk Factors, Acute Management, Special Populations and Prevention - [118]
Hsu KL, Fink JC, Ginsberg JS et al.. “Self-reported Medication Adherence and Adverse Patient Safety Events in CKD.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2015). PMID: 25979348 ↗
L4OTHERCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup, Staging and Risk Stratification (KDIGO), Prognosis and Natural History - [119]
Tear AA, Fauziah N, Riswari SF et al.. “Prognostic factors in malaria patients with acute kidney injury: a systematic review and meta analysis.” Renal failure (2026). PMID: 42185742 ↗
L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Clinical Presentation, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Complications - [120]
Zhu Y, Li J, Huang Z et al.. “Mineralocorticoid receptor antagonists in dialysis patients after ACHIEVE and ALCHEMIST: updated systematic review and meta-analysis of 14 randomized trials.” Renal failure (2026). PMID: 42056760 ↗
L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Acute Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Complications, Prognosis and Natural History - [121]
Riaz AA, Abrar Z, Cheema FF et al.. “Safety and efficacy of novel potassium binders for chronic hyperkalemia: a systematic review and meta-analysis of randomized controlled trials.” Proceedings (Baylor University. Medical Center) (2025). PMID: 41487544 ↗
L1SR_MA_RCTCited in: Epidemiology, Etiology and Risk Factors - [122]
Montford JR, Linas S. “How Dangerous Is Hyperkalemia?” Journal of the American Society of Nephrology : JASN (2017). PMID: 28778861 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Clinical Presentation, Acute Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Complications - [123]
Ruggenenti P, Perticucci E, Cravedi P et al.. “Role of remission clinics in the longitudinal treatment of CKD.” Journal of the American Society of Nephrology : JASN (2008). PMID: 18354029 ↗
L2OTHERCited in: Epidemiology, Etiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Long-term and Definitive Management, Prognosis and Natural History - [124]
Ginsberg JS, Zhan M, Diamantidis CJ et al.. “Patient-reported and actionable safety events in CKD.” Journal of the American Society of Nephrology : JASN (2014). PMID: 24556352 ↗
L4OTHERCited in: Epidemiology, Etiology and Risk Factors, Complications, Special Populations and Prevention - [125]
Geller DS, Zhang J, Zennaro MC et al.. “Autosomal dominant pseudohypoaldosteronism type 1: mechanisms, evidence for neonatal lethality, and phenotypic expression in adults.” Journal of the American Society of Nephrology : JASN (2006). PMID: 16611713 ↗
L4OTHERCited in: Epidemiology, Etiology and Risk Factors, Staging and Risk Stratification (KDIGO) - [126]
Deng Z, Fu W, Chen F et al.. “Association between low-dose trimethoprim-sulfamethoxazole blood concentration and clinical outcomes in non-HIV patients with Pneumocystis jirovecii pneumonia: a retrospective cohort study.” BMC infectious diseases (2026). PMID: 41772486 ↗
L3COHORTCited in: Epidemiology, Etiology and Risk Factors - [127]
Gregoire S, Dewey E, Sanchez K et al.. “Hyperkalemia incidence in females over 45 years old on spironolactone for dermatologic conditions: A retrospective cohort study.” Journal of the American Academy of Dermatology (2026). PMID: 41655839 ↗
L3COHORTCited in: Epidemiology, Etiology and Risk Factors, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Special Populations and Prevention - [128]
Hu Y, Hu W, Li D et al.. “Reassessing the efficacy and safety of trimethoprim-sulfamethoxazole for Pneumocystis jirovecii pneumonia: a retrospective study.” European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology (2026). PMID: 41563564 ↗
L3COHORTCited in: Epidemiology, Etiology and Risk Factors - [129]
Idemitsu R, Nagai T, Matsui H et al.. “Risk factors for adverse events associated with trimethoprim-sulfamethoxazole treatment for Pneumocystis pneumonia in non-human immunodeficiency virus-infected patients: a multicenter, retrospective, observational cohort study.” BMC infectious diseases (2026). PMID: 41559609 ↗
L3COHORTCited in: Epidemiology, Etiology and Risk Factors - [130]
Bernier-Jean A, Wong G, Saglimbene V et al.. “Dietary Potassium Intake and All-Cause Mortality in Adults Treated with Hemodialysis.” Clinical journal of the American Society of Nephrology : CJASN (2021). PMID: 34853064 ↗
L3OTHERCited in: Epidemiology, Etiology and Risk Factors, Acute Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Complications, Prognosis and Natural History - [131]
Kliger AS. “Maintaining safety in the dialysis facility.” Clinical journal of the American Society of Nephrology : CJASN (2014). PMID: 25376767 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Staging and Risk Stratification (KDIGO), Acute Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management - [132]
Hundemer GL, Talarico R, Tangri N et al.. “Ambulatory Treatments for RAAS Inhibitor-Related Hyperkalemia and the 1-Year Risk of Recurrence.” Clinical journal of the American Society of Nephrology : CJASN (2021). PMID: 33608262 ↗
L3OTHERCited in: Epidemiology, Etiology and Risk Factors, Staging and Risk Stratification (KDIGO), Acute Management, Special Populations and Prevention - [133]
Rossing P, Birkenfeld AL, Fioretto P et al.. “Finerenone and Clinical Outcomes in CKD and Type 2 Diabetes by Frailty Index: FIDELITY Post Hoc Analysis.” Clinical journal of the American Society of Nephrology : CJASN (2025). PMID: 40315020 ↗
L3OTHERCited in: Epidemiology, Etiology and Risk Factors - [134]
Avesani CM, Cecchini V, Sabatino A et al.. “Ultra-Processed Foods and Food Additives in CKD: Unveiling Hidden Risks and Advocating Smarter Food Choices.” Clinical journal of the American Society of Nephrology : CJASN (2025). PMID: 40512553 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors - [135]
Sarafidis PA, Blacklock R, Wood E et al.. “Prevalence and factors associated with hyperkalemia in predialysis patients followed in a low-clearance clinic.” Clinical journal of the American Society of Nephrology : CJASN (2012). PMID: 22595825 ↗
L4OTHERCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup - [136]
Bosi A, Xu Y, Faucon AL et al.. “Hyperkalemia and maintenance of renin-angiotensin system inhibitor therapy after initiating SGLT-2 or DPP-4 inhibitors.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2025). PMID: 39384578 ↗
L3OTHERCited in: Epidemiology, Etiology and Risk Factors, Special Populations and Prevention - [137]
Wetmore JB, Yan H, Horne L et al.. “Risk of hyperkalemia from renin-angiotensin-aldosterone system inhibitors and factors associated with treatment discontinuities in a real-world population.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2021). PMID: 31846025 ↗
L3OTHERCited in: Epidemiology, Etiology and Risk Factors, Special Populations and Prevention - [138]
Seethapathy H, Rusibamayila N, Chute DF et al.. “Hyponatremia and other electrolyte abnormalities in patients receiving immune checkpoint inhibitors.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2021). PMID: 33374011 ↗
L3OTHERCited in: Epidemiology, Etiology and Risk Factors - [139]
Charytan DM, Winkelmayer WC, Granger CB et al.. “Effects of dialysate potassium concentration of 3.0 mmol/l with sodium zirconium cyclosilicate on dialysis-free days versus dialysate potassium concentration of 2.0 mmol/l alone on rates of cardiac arrhythmias in hemodialysis patients with hyperkalemia.” Kidney international (2024). PMID: 39490411 ↗
L1RCTCited in: Clinical Presentation, Diagnosis and Workup, Acute Management, Long-term and Definitive Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Complications, Special Populations and Prevention - [140]
Ash SR, Singh B, Lavin PT et al.. “A phase 2 study on the treatment of hyperkalemia in patients with chronic kidney disease suggests that the selective potassium trap, ZS-9, is safe and efficient.” Kidney international (2015). PMID: 25651363 ↗
L1RCTCited in: Clinical Presentation, Special Populations and Prevention - [141]
Bianchi S, Bigazzi R, Campese VM. “Intensive versus conventional therapy to slow the progression of idiopathic glomerular diseases.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2010). PMID: 20097461 ↗
L1RCTCited in: Clinical Presentation, Diagnosis and Workup, Prognosis and Natural History - [142]
Navaneethan SD, Nigwekar SU, Sehgal AR et al.. “Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis.” Clinical journal of the American Society of Nephrology : CJASN (2009). PMID: 19261819 ↗
L1SR_OBSCited in: Clinical Presentation, Diagnosis and Workup, Staging and Risk Stratification (KDIGO), Long-term and Definitive Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Complications, Prognosis and Natural History - [143]
Velazquez EJ, Morrow DA, DeVore AD et al.. “Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure.” The New England journal of medicine (2018). PMID: 30415601 ↗
L1RCTCited in: Clinical Presentation, Long-term and Definitive Management, Complications, Special Populations and Prevention - [144]
Lepage L, Dufour AC, Doiron J et al.. “Randomized Clinical Trial of Sodium Polystyrene Sulfonate for the Treatment of Mild Hyperkalemia in CKD.” Clinical journal of the American Society of Nephrology : CJASN (2015). PMID: 26576619 ↗
L1RCTCited in: Clinical Presentation, Long-term and Definitive Management - [145]
Ito S, Shikata K, Nangaku M et al.. “Efficacy and Safety of Esaxerenone (CS-3150) for the Treatment of Type 2 Diabetes with Microalbuminuria: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial.” Clinical journal of the American Society of Nephrology : CJASN (2019). PMID: 31248950 ↗
L1RCTCited in: Clinical Presentation, Staging and Risk Stratification (KDIGO) - [146]
Edwards NC, Price AM, Mehta S et al.. “Effects of Spironolactone and Chlorthalidone on Cardiovascular Structure and Function in Chronic Kidney Disease: A Randomized, Open-Label Trial.” Clinical journal of the American Society of Nephrology : CJASN (2021). PMID: 34462286 ↗
L1RCTCited in: Clinical Presentation, Diagnosis and Workup, Prognosis and Natural History, Special Populations and Prevention - [147]
Epstein M, Williams GH, Weinberger M et al.. “Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes.” Clinical journal of the American Society of Nephrology : CJASN (2006). PMID: 17699311 ↗
L1RCTCited in: Clinical Presentation - [148]
Esteghamati A, Noshad S, Jarrah S et al.. “Long-term effects of addition of mineralocorticoid receptor antagonist to angiotensin II receptor blocker in patients with diabetic nephropathy: a randomized clinical trial.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2013). PMID: 24009294 ↗
L1RCTCited in: Clinical Presentation - [149]
Ascher SB, Scherzer R, Estrella MM et al.. “Kidney tubule health, mineral metabolism and adverse events in persons with CKD in SPRINT.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2022). PMID: 34473302 ↗
L3TRIAL_NONRANDOMCited in: Clinical Presentation, Diagnosis and Workup, Staging and Risk Stratification (KDIGO), Complications, Prognosis and Natural History, Special Populations and Prevention - [150]
Tang SC, Lin M, Tam S et al.. “Aliskiren combined with losartan in immunoglobulin A nephropathy: an open-labeled pilot study.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2011). PMID: 21680850 ↗
L4TRIAL_NONRANDOMCited in: Clinical Presentation, Diagnosis and Workup, Staging and Risk Stratification (KDIGO) - [151]
Cai J, Huang X, Zheng Z et al.. “Comparative efficacy of individual renin-angiotensin system inhibitors on major renal outcomes in diabetic kidney disease: a network meta-analysis.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2018). PMID: 29579289 ↗
L1SR_OBSCited in: Clinical Presentation, Staging and Risk Stratification (KDIGO) - [152]
Leclerc S, Royal V, Lamarche C et al.. “Minimal Change Disease With Severe Acute Kidney Injury Following the Oxford-AstraZeneca COVID-19 Vaccine: A Case Report.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2021). PMID: 34242687 ↗
L4CASE_REPORTCited in: Clinical Presentation, Diagnosis and Workup, Staging and Risk Stratification (KDIGO), Special Populations and Prevention - [153]
Shingarev R, Allon M. “A physiologic-based approach to the treatment of acute hyperkalemia.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2010). PMID: 20570423 ↗
L5CASE_REPORTCited in: Clinical Presentation, Special Populations and Prevention - [154]
Vigneau C, Daugas E, Maury E et al.. “Renal cortical necrosis related to paraneoplastic antiphospholipid syndrome.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2006). PMID: 16731303 ↗
L4CASE_REPORTCited in: Clinical Presentation, Diagnosis and Workup - [155]
Kim JO, Kim GH, Kang CM et al.. “Bilateral acute renal cortical necrosis in SLE-associated antiphospholipid syndrome.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2011). PMID: 21514023 ↗
L4CASE_REPORTCited in: Clinical Presentation - [156]
Bakris GL, Ruilope LM, Anker SD et al.. “A prespecified exploratory analysis from FIDELITY examined finerenone use and kidney outcomes in patients with chronic kidney disease and type 2 diabetes.” Kidney international (2022). PMID: 36367466 ↗
L1OTHERCited in: Clinical Presentation, Diagnosis and Workup, Long-term and Definitive Management, Complications, Prognosis and Natural History - [157]
Sterns RH, Grieff M, Bernstein PL. “Treatment of hyperkalemia: something old, something new.” Kidney international (2016). PMID: 26880451 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Diagnosis and Workup, Acute Management, Long-term and Definitive Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management - [158]
Bagchi S, Husain Zaidi S, Prasad Mathur R. “Severe symptomatic hyponatremia--an uncommon presentation of tacrolimus nephrotoxicity.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2011). PMID: 21454354 ↗
L4CASE_REPORTCited in: Clinical Presentation - [159]
Li SG, Long T, Yu R et al.. “Adrenal involvement in antiphospholipid syndrome and SLE-spectrum disease: a systematic review and pooled individual-patient analysis.” Frontiers in immunology (2026). PMID: 42317308 ↗
L3SR_OBSCited in: Clinical Presentation, Complications - [160]
Cohen DL, Townsend RR. “Is there added value to adding ARB to ACE inhibitors in the management of CKD?” Journal of the American Society of Nephrology : JASN (2008). PMID: 18776118 ↗
L5OTHERCited in: Clinical Presentation, Diagnosis and Workup - [161]
Harmon DM, Liu K, Dugan J et al.. “Validation of Noninvasive Detection of Hyperkalemia by Artificial Intelligence-Enhanced Electrocardiography in High Acuity Settings.” Clinical journal of the American Society of Nephrology : CJASN (2024). PMID: 39116276 ↗
L3OTHERCited in: Clinical Presentation, Diagnosis and Workup - [162]
Palmer BF, Clegg DJ. “Hyperkalemia treatment standard.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2024). PMID: 38425037 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Diagnosis and Workup, Acute Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management - [163]
Pérez-Mir M, Canal Girol C, Escolà-Vergé L et al.. “Antibiotic Tolerability in Nocardia Infection Among Kidney Transplant Recipients: A Multicenter Cohort Study.” Transplant infectious disease : an official journal of the Transplantation Society (2026). PMID: 42142207 ↗
L3COHORTCited in: Clinical Presentation - [164]
Wathanavasin W, Jaturapisanukul S, Thongprayoon C et al.. “Efficacy and Tolerability of Sodium Zirconium Cyclosilicate or Patiromer in Managing Hyperkalemia: A Systematic Review and Meta-Analysis.” Kidney360 (2026). PMID: 41811379 ↗
L1SR_OBSCited in: Clinical Presentation - [165]
Better OS, Abassi ZA. “Early fluid resuscitation in patients with rhabdomyolysis.” Nature reviews. Nephrology (2011). PMID: 21587227 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Acute Management, Complications - [166]
Chen K, Shao W, Zhang H. “Meta-analysis of the efficacy and safety of Finerenone in diabetic kidney disease.” Medicine (2026). PMID: 41578591 ↗
L1SR_OBSCited in: Clinical Presentation - [167]
Zhang R, Zhang Y, Nie Y et al.. “Coexistence of 21-hydroxylase deficiency and Gitelman syndrome in a neonate presenting with severe hyponatremic seizures: a case report.” Frontiers in endocrinology (2026). PMID: 42358677 ↗
L4CASE_REPORTCited in: Clinical Presentation, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management - [168]
Morrissey B. “Acute urinary retention presenting as inferior pseudo-STEMI: A case report.” The American journal of emergency medicine (2026). PMID: 42330710 ↗
L4CASE_REPORTCited in: Clinical Presentation - [169]
Bushinsky DA, Spiegel DM, Yuan J et al.. “Effects of the Potassium-Binding Polymer Patiromer on Markers of Mineral Metabolism.” Clinical journal of the American Society of Nephrology : CJASN (2018). PMID: 30381412 ↗
L1RCTCited in: Diagnosis and Workup, Prognosis and Natural History, Special Populations and Prevention - [170]
Tang SCW, Chan KW, Ip DKM et al.. “Direct Renin Inhibition in Non-diabetic chronic Kidney disease (DRINK): a prospective randomized trial.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2021). PMID: 32617578 ↗
L1RCTCited in: Diagnosis and Workup, Complications, Prognosis and Natural History, Special Populations and Prevention - [171]
Hsu CY, Propert K, Xie D et al.. “Measured GFR does not outperform estimated GFR in predicting CKD-related complications.” Journal of the American Society of Nephrology : JASN (2011). PMID: 21921144 ↗
L2TRIAL_NONRANDOMCited in: Diagnosis and Workup, Prognosis and Natural History, Special Populations and Prevention - [172]
Palmer BF. “A physiologic-based approach to the evaluation of a patient with hyperkalemia.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2010). PMID: 20493606 ↗
L5CASE_REPORTCited in: Diagnosis and Workup - [173]
Butler MJ, Ramnath R, Kadoya H et al.. “Aldosterone induces albuminuria via matrix metalloproteinase-dependent damage of the endothelial glycocalyx.” Kidney international (2018). PMID: 30389198 ↗
L5OTHERCited in: Diagnosis and Workup, Staging and Risk Stratification (KDIGO) - [174]
Tsutsumi YM, Nagasaka H, Mukaida K et al.. “JSA guideline for management of malignant hyperthermia in 2025.” Journal of anesthesia (2026). PMID: 41504952 ↗
L1GUIDELINECited in: Diagnosis and Workup - [175]
Diamantidis CJ, Seliger SL, Zhan M et al.. “A varying patient safety profile between black and nonblack adults with decreased estimated GFR.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2012). PMID: 22483674 ↗
L3OTHERCited in: Diagnosis and Workup - [176]
Liu BC, Yang LL, Lu XY et al.. “Lovastatin-Induced Phosphatidylinositol-4-Phosphate 5-Kinase Diffusion from Microvilli Stimulates ROMK Channels.” Journal of the American Society of Nephrology : JASN (2014). PMID: 25349201 ↗
L5OTHERCited in: Diagnosis and Workup - [177]
Wu CR, Chang YC, Tranyor V et al.. “Machine learning-based prediction of delirium in older patients with chronic kidney disease requiring intensive care: A hospital-based retrospective cohort study.” Journal of psychosomatic research (2025). PMID: 41265364 ↗
L3COHORTCited in: Diagnosis and Workup - [178]
Liu X, Lin Q, Gao K et al.. “Association between serum potassium and 28-day mortality in elderly patients with sepsis: a multicenter cohort study.” BMC geriatrics (2025). PMID: 41225362 ↗
L3COHORTCited in: Diagnosis and Workup - [179]
Luo J, Brunelli SM, Jensen DE et al.. “Association between Serum Potassium and Outcomes in Patients with Reduced Kidney Function.” Clinical journal of the American Society of Nephrology : CJASN (2015). PMID: 26500246 ↗
L3OTHERCited in: Diagnosis and Workup - [180]
Ronksley PE, Hemmelgarn BR, Manns BJ et al.. “Potentially Preventable Hospitalization among Patients with CKD and High Inpatient Use.” Clinical journal of the American Society of Nephrology : CJASN (2016). PMID: 27821636 ↗
L3OTHERCited in: Diagnosis and Workup - [181]
Hughes-Austin JM, Rifkin DE, Beben T et al.. “The Relation of Serum Potassium Concentration with Cardiovascular Events and Mortality in Community-Living Individuals.” Clinical journal of the American Society of Nephrology : CJASN (2017). PMID: 28143865 ↗
L3OTHERCited in: Diagnosis and Workup - [182]
Libório AB, Leite TT, Neves FM et al.. “AKI complications in critically ill patients: association with mortality rates and RRT.” Clinical journal of the American Society of Nephrology : CJASN (2014). PMID: 25376761 ↗
L3OTHERCited in: Diagnosis and Workup - [183]
Raza SA, Rehman AU, Aamir AH et al.. “Comparative efficacy and safety of finerenone in diabetic kidney disease: a meta-analysis of Asian and non-Asian populations.” BMC nephrology (2025). PMID: 41272492 ↗
L1SR_OBSCited in: Diagnosis and Workup, Long-term and Definitive Management - [184]
Granal M, Fouque D, Ducher M et al.. “Factors associated with kalemia in renal disease.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2023). PMID: 36662047 ↗
L3OTHERCited in: Diagnosis and Workup, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Complications, Prognosis and Natural History - [185]
Gritter M, Wei KY, Wouda RD et al.. “Chronic kidney disease increases the susceptibility to negative effects of low and high potassium intake.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2024). PMID: 37813819 ↗
L4OTHERCited in: Diagnosis and Workup, Prognosis and Natural History - [186]
Nash DM, Markle-Reid M, Brimble KS et al.. “Nonsteroidal anti-inflammatory drug use and risk of acute kidney injury and hyperkalemia in older adults: a population-based study.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2019). PMID: 31264694 ↗
L3OTHERCited in: Diagnosis and Workup, Staging and Risk Stratification (KDIGO), Special Populations and Prevention - [187]
Okparavero A, Foster MC, Tighiouart H et al.. “Prevalence and complications of chronic kidney disease in a representative elderly population in Iceland.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2015). PMID: 26519958 ↗
L2OTHERCited in: Diagnosis and Workup - [188]
Martinez Y, Vilches M, Gil S et al.. “Incidence and predictors of hyperkalemia after subtotal parathyroidectomy in pediatric chronic dialysis patients with secondary hyperparathyroidism: a retrospective cohort study.” BMC nephrology (2025). PMID: 41146065 ↗
L4COHORTCited in: Diagnosis and Workup, Acute Management - [189]
Katayama S, Anker SD, Zhu D et al.. “Efficacy and safety of finerenone in Asian patients with type 2 diabetes and chronic kidney disease: A FIDELITY analysis by baseline kidney function.” Journal of diabetes and its complications (2025). PMID: 41289823 ↗
L1RCTCited in: Diagnosis and Workup, Long-term and Definitive Management - [190]
Cheung AK, Chang TI, Cushman WC et al.. “Executive summary of the KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease.” Kidney international (2021). PMID: 33637203 ↗
L1GUIDELINECited in: Staging and Risk Stratification (KDIGO), Acute Management, Long-term and Definitive Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Special Populations and Prevention - [191]
Korgaonkar S, Tilea A, Gillespie BW et al.. “Serum potassium and outcomes in CKD: insights from the RRI-CKD cohort study.” Clinical journal of the American Society of Nephrology : CJASN (2010). PMID: 20203167 ↗
L2COHORTCited in: Staging and Risk Stratification (KDIGO) - [192]
Weir MA, Juurlink DN, Gomes T et al.. “Beta-blockers, trimethoprim-sulfamethoxazole, and the risk of hyperkalemia requiring hospitalization in the elderly: a nested case-control study.” Clinical journal of the American Society of Nephrology : CJASN (2010). PMID: 20595693 ↗
L3CASE_CONTROLCited in: Staging and Risk Stratification (KDIGO) - [193]
Shen JI, Winkelmayer WC. “Use and safety of unfractionated heparin for anticoagulation during maintenance hemodialysis.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2012). PMID: 22560830 ↗
L5CASE_REPORTCited in: Staging and Risk Stratification (KDIGO), Acute Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Prognosis and Natural History - [194]
Seimiya M, Yoshida T, Sawabe Y et al.. “Reducing the incidence of pseudohyperkalemia by avoiding making a fist during phlebotomy: a quality improvement report.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2010). PMID: 20801569 ↗
L4OTHERCited in: Staging and Risk Stratification (KDIGO) - [195]
Brunelli SM, Du Mond C, Oestreicher N et al.. “Serum Potassium and Short-term Clinical Outcomes Among Hemodialysis Patients: Impact of the Long Interdialytic Interval.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2017). PMID: 28111027 ↗
L3OTHERCited in: Staging and Risk Stratification (KDIGO), Acute Management - [196]
Roy P, Bouchard J, Amyot R et al.. “Prescription patterns of pharmacological agents for left ventricular systolic dysfunction among hemodialysis patients.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2006). PMID: 16997061 ↗
L4OTHERCited in: Staging and Risk Stratification (KDIGO), Acute Management - [197]
Karaboyas A, Zee J, Brunelli SM et al.. “Dialysate Potassium, Serum Potassium, Mortality, and Arrhythmia Events in Hemodialysis: Results From the Dialysis Outcomes and Practice Patterns Study (DOPPS).” American journal of kidney diseases : the official journal of the National Kidney Foundation (2016). PMID: 27866964 ↗
L2OTHERCited in: Staging and Risk Stratification (KDIGO), Acute Management - [198]
Yuan CY, Gao YC, Lin Y et al.. “Effects of Mineralocorticoid Receptor Antagonists for Chronic Kidney Disease: A Systemic Review and Meta-Analysis.” American journal of nephrology (2023). PMID: 37793348 ↗
L1SR_OBSCited in: Staging and Risk Stratification (KDIGO) - [199]
Perrier R, Boscardin E, Malsure S et al.. “Severe Salt-Losing Syndrome and Hyperkalemia Induced by Adult Nephron-Specific Knockout of the Epithelial Sodium Channel α-Subunit.” Journal of the American Society of Nephrology : JASN (2015). PMID: 26701978 ↗
L5OTHERCited in: Staging and Risk Stratification (KDIGO) - [200]
Pannu N, McBrien KA, Tan Z et al.. “Advancing Community Care and Access to Follow-Up after Acute Kidney Injury Hospitalization: A Randomized Clinical Trial.” Journal of the American Society of Nephrology : JASN (2024). PMID: 39446571 ↗
L1OTHERCited in: Staging and Risk Stratification (KDIGO) - [201]
Agarwal R, Green JB, Heerspink HJL et al.. “Impact of Baseline GLP-1 Receptor Agonist Use on Albuminuria Reduction and Safety With Simultaneous Initiation of Finerenone and Empagliflozin in Type 2 Diabetes and Chronic Kidney Disease (CONFIDENCE Trial).” Diabetes care (2025). PMID: 40968755 ↗
L1RCTCited in: Staging and Risk Stratification (KDIGO), Prognosis and Natural History - [202]
Ostrominski JW, Mc Causland FR, Claggett BL et al.. “Finerenone Across the Spectrum of Kidney Risk in Heart Failure: The FINEARTS-HF Trial.” JACC. Heart failure (2025). PMID: 40208137 ↗
L1RCTCited in: Staging and Risk Stratification (KDIGO) - [203]
Sun J, Liu Q, Seery S et al.. “The impact of hyperkalemia on ICU admission and mortality: a retrospective study of Chinese emergency department data.” BMC emergency medicine (2024). PMID: 38824546 ↗
L2COHORTCited in: Staging and Risk Stratification (KDIGO) - [204]
Zheng Q, Wang Y, Yang H et al.. “Cardiac and Kidney Adverse Effects of HIF Prolyl-Hydroxylase Inhibitors for Anemia in Patients With CKD Not Receiving Dialysis: A Systematic Review and Meta-analysis.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2022). PMID: 36396085 ↗
L1SR_OBSCited in: Acute Management, Long-term and Definitive Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Complications - [205]
Sawinski D, Lindner H, Fitzsimmons R et al.. “Dialysis Nonadherence and Kidney Transplant Outcomes: A Retrospective Cohort Study.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2021). PMID: 34673160 ↗
L2COHORTCited in: Acute Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Prognosis and Natural History - [206]
Pichitporn W, Kanjanabuch T, Phannajit J et al.. “Efficacy of Potassium Supplementation in Hypokalemic Patients Receiving Peritoneal Dialysis: A Randomized Controlled Trial.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2022). PMID: 35597332 ↗
L1RCTCited in: Acute Management, Long-term and Definitive Management - [207]
Chen KT, Kang YN, Lin YC et al.. “Efficacy and Safety of Mineralocorticoid Receptor Antagonists in Kidney Failure Patients Treated with Dialysis: A Systematic Review and Meta-Analysis.” Clinical journal of the American Society of Nephrology : CJASN (2021). PMID: 34117083 ↗
L1SR_OBSCited in: Acute Management, Complications, Prognosis and Natural History - [208]
Ito Y, Mizuno M, Suzuki Y et al.. “Long-term effects of spironolactone in peritoneal dialysis patients.” Journal of the American Society of Nephrology : JASN (2013). PMID: 24335969 ↗
L1RCTCited in: Acute Management, Long-term and Definitive Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Complications, Prognosis and Natural History, Special Populations and Prevention - [209]
Chen N, Hao C, Liu BC et al.. “Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis.” The New England journal of medicine (2019). PMID: 31340116 ↗
L1RCTCited in: Acute Management, Long-term and Definitive Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management - [210]
Vollmer Barbosa C, Lang H, Melk A et al.. “Renal events in patients receiving neprilysin inhibitors: a systematic review and meta-analysis.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2022). PMID: 35022763 ↗
L1SR_OBSCited in: Acute Management, Long-term and Definitive Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management - [211]
Albakr RB, Sridhar VS, Cherney DZI. “Novel Therapies in Diabetic Kidney Disease and Risk of Hyperkalemia: A Review of the Evidence From Clinical Trials.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2023). PMID: 37517546 ↗
L5TRIAL_NONRANDOMCited in: Acute Management, Long-term and Definitive Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Complications - [212]
Bushinsky DA, Budden JJ, Kalra PA et al.. “Patiromer Treatment in Patients With CKD, Hyperkalemia, and Hyperphosphatemia: A Post Hoc Analysis of 3 Clinical Trials.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2023). PMID: 36965827 ↗
L2TRIAL_NONRANDOMCited in: Acute Management - [213]
Walsh M, Manns B, Garg AX et al.. “The Safety of Eplerenone in Hemodialysis Patients: A Noninferiority Randomized Controlled Trial.” Clinical journal of the American Society of Nephrology : CJASN (2015). PMID: 26138259 ↗
L1RCTCited in: Acute Management, Complications, Prognosis and Natural History, Special Populations and Prevention - [214]
Cao D, Arens AM, Chow SL et al.. “Part 10: Adult and Pediatric Special Circumstances of Resuscitation: 2025 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care.” Circulation (2025). PMID: 41122889 ↗
L1GUIDELINECited in: Acute Management, Special Populations and Prevention - [215]
Ravi KS, Mc Causland FR. “Where next for potassium binders in hemodialysis?” Kidney international (2025). PMID: 40975524 ↗
L5OTHERCited in: Acute Management, Long-term and Definitive Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Complications, Prognosis and Natural History - [216]
Palmer BF, Clegg DJ. “Gastrointestinal potassium binding in hemodialysis.” Kidney international (2020). PMID: 33126973 ↗
L5OTHERCited in: Acute Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Prognosis and Natural History - [217]
Bragg-Gresham JL, Fissell RB, Mason NA et al.. “Diuretic use, residual renal function, and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Pattern Study (DOPPS).” American journal of kidney diseases : the official journal of the National Kidney Foundation (2007). PMID: 17336704 ↗
L2OTHERCited in: Acute Management - [218]
Gorayeb-Polacchini FS, Moraes TP, Elias RM et al.. “Position Statement of the Brazilian Society of Nephrology on incremental dialysis.” Jornal brasileiro de nefrologia (2026). PMID: 42361228 ↗
L1GUIDELINECited in: Acute Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management - [219]
Ellison DH, Terker AS, Gamba G. “Potassium and Its Discontents: New Insight, New Treatments.” Journal of the American Society of Nephrology : JASN (2015). PMID: 26510885 ↗
L5REVIEW_NARRATIVECited in: Acute Management, Long-term and Definitive Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management - [220]
Boscardin E, Perrier R, Sergi C et al.. “Plasma Potassium Determines NCC Abundance in Adult Kidney-Specific γENaC Knockout.” Journal of the American Society of Nephrology : JASN (2018). PMID: 29371419 ↗
L5OTHERCited in: Acute Management, Long-term and Definitive Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management - [221]
Sterns RH, Rojas M, Bernstein P et al.. “Ion-exchange resins for the treatment of hyperkalemia: are they safe and effective?” Journal of the American Society of Nephrology : JASN (2010). PMID: 20167700 ↗
L5OTHERCited in: Acute Management, Long-term and Definitive Management - [222]
Siebert JN, Cheng A, De Masi A et al.. “Augmented Reality-Guided Decision Support in Simulated Pediatric Cardiac Arrest: A Randomized Clinical Trial.” JAMA network open (2026). PMID: 42172032 ↗
L1RCTCited in: Acute Management, Long-term and Definitive Management, Complications, Special Populations and Prevention - [223]
Russ P, Morgenschweis M, Einloft J et al.. “Novel Immersive Emergency Training Module to Enhance Clinical Competency in Nephrology.” Clinical journal of the American Society of Nephrology : CJASN (2025). PMID: 40658484 ↗
L5OTHERCited in: Acute Management - [224]
Ronksley PE, Tonelli M, Manns BJ et al.. “Emergency Department Use among Patients with CKD: A Population-Based Analysis.” Clinical journal of the American Society of Nephrology : CJASN (2017). PMID: 28119410 ↗
L2OTHERCited in: Acute Management, Special Populations and Prevention - [225]
Saglimbene VM, Wong G, Ruospo M et al.. “Fruit and Vegetable Intake and Mortality in Adults undergoing Maintenance Hemodialysis.” Clinical journal of the American Society of Nephrology : CJASN (2019). PMID: 31738182 ↗
L2OTHERCited in: Acute Management, Complications, Prognosis and Natural History - [226]
Vaara ST, Reinikainen M, Wald R et al.. “Timing of RRT based on the presence of conventional indications.” Clinical journal of the American Society of Nephrology : CJASN (2014). PMID: 25107952 ↗
L2OTHERCited in: Acute Management - [227]
St-Jules DE, Clegg DJ, Palmer BF et al.. “Can Novel Potassium Binders Liberate People with Chronic Kidney Disease from the Low-Potassium Diet? A Cautionary Tale.” Clinical journal of the American Society of Nephrology : CJASN (2021). PMID: 34670798 ↗
L5REVIEW_NARRATIVECited in: Acute Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management - [228]
Watson M, Abbott KC, Yuan CM. “Damned if you do, damned if you don't: potassium binding resins in hyperkalemia.” Clinical journal of the American Society of Nephrology : CJASN (2010). PMID: 20798253 ↗
L5OTHERCited in: Acute Management - [229]
Bridgeman MB, Shah M, Foote E. “Potassium-lowering agents for the treatment of nonemergent hyperkalemia: pharmacology, dosing and comparative efficacy.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2019). PMID: 31800078 ↗
L5REVIEW_NARRATIVECited in: Acute Management, Long-term and Definitive Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management - [230]
Gregg LP, Navaneethan SD. “Steroidal or non-steroidal MRAs: should we still enable RAASi use through K binders?” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2023). PMID: 36264349 ↗
L5OTHERCited in: Acute Management, Long-term and Definitive Management, Prognosis and Natural History - [231]
Arif Y, Wenziger C, Hsiung JT et al.. “Association of serum potassium with decline in residual kidney function in incident hemodialysis patients.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2022). PMID: 35561740 ↗
L3OTHERCited in: Acute Management - [232]
Janjua HS, Mahan JD, Patel HP et al.. “Continuous infusion of a standard combination solution in the management of hyperkalemia.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2011). PMID: 21220753 ↗
L4OTHERCited in: Acute Management - [233]
Ramos CI, González-Ortiz A, Espinosa-Cuevas A et al.. “Does dietary potassium intake associate with hyperkalemia in patients with chronic kidney disease?” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2021). PMID: 33247727 ↗
L3OTHERCited in: Acute Management, Special Populations and Prevention - [234]
Deak AT, Belić K, Meissl AM et al.. “Salivary potassium measured by genetically encoded potassium ion indicators as a surrogate for plasma potassium levels in hemodialysis patients-a proof-of-concept study.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2023). PMID: 35700151 ↗
L4OTHERCited in: Acute Management - [235]
Silva CLD, Fonseca PEO, Calice-Silva V et al.. “Efficacy and safety of sacubitril/valsartan in patients on peritoneal dialysis: a systematic review and meta-analysis.” Jornal brasileiro de nefrologia (2026). PMID: 41931676 ↗
L1SR_OBSCited in: Acute Management, Long-term and Definitive Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management - [236]
Moncho-Francés F, Gonzales-Candia B, Perez-Silvestre J et al.. “Real-world use of patiromer in patients with hyperkalaemia: A retrospective study from the Valencian Community.” Nefrologia (2026). PMID: 41791977 ↗
L3COHORTCited in: Acute Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management - [237]
Chandra A, Rao N, Kulshreshtha MR. “Controlled potassium reduction using dialysate profiling in hyperkalemic hemodialysis patients: A randomized study.” The International journal of artificial organs (2025). PMID: 41185428 ↗
L1RCTCited in: Acute Management - [238]
Nasiri H, Mirmazhari A, Mirzakhani L et al.. “Network meta-analysis of HIF-prolyl hydroxylase inhibitors for anemia in dialysis-dependent and non-dialysis CKD: effects on hemoglobin, iron markers, and adverse clinical outcomes.” BMC nephrology (2025). PMID: 41239296 ↗
L1SR_OBSCited in: Acute Management - [239]
Kaisar MO, Wiggins KJ, Sturtevant JM et al.. “A randomized controlled trial of fludrocortisone for the treatment of hyperkalemia in hemodialysis patients.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2006). PMID: 16632019 ↗
L1RCTCited in: Long-term and Definitive Management - [240]
Desai AS, Webb DJ, Taubel J et al.. “Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension.” The New England journal of medicine (2023). PMID: 37467498 ↗
L1RCTCited in: Long-term and Definitive Management, Complications - [241]
Jøns C, Zheng C, Winsløw UCG et al.. “Increasing the Potassium Level in Patients at High Risk for Ventricular Arrhythmias.” The New England journal of medicine (2025). PMID: 40879429 ↗
L1TRIAL_NONRANDOMCited in: Long-term and Definitive Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management - [242]
Green JB, Mottl AK, Bakris G et al.. “Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE).” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2023). PMID: 35700142 ↗
L2TRIAL_NONRANDOMCited in: Long-term and Definitive Management, Complications - [243]
Chen JJ, Lee TH, Yang HY. “Exploring nontraditional cardiorenal advantages of SGLT-2 inhibitors and GLP-1 receptor agonists.” Kidney international (2024). PMID: 38388145 ↗
L5OTHERCited in: Long-term and Definitive Management - [244]
Muhammad Daniyal S, Ajaz H, Riaz M et al.. “Combination therapy with mineralocorticoid receptor antagonists and SGLT2 inhibitors versus SGLT2 inhibitor monotherapy in chronic kidney disease: an updated meta-analysis of randomized controlled trials.” BMC nephrology (2025). PMID: 41430169 ↗
L1SR_MA_RCTCited in: Long-term and Definitive Management - [245]
Baker M, Perazella MA. “NSAIDs in CKD: Are They Safe?” American journal of kidney diseases : the official journal of the National Kidney Foundation (2020). PMID: 32479922 ↗
L5REVIEW_NARRATIVECited in: Long-term and Definitive Management, Complications - [246]
Epstein M, Kovesdy CP, Clase CM et al.. “Aldosterone, Mineralocorticoid Receptor Activation, and CKD: A Review of Evolving Treatment Paradigms.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2022). PMID: 36057467 ↗
L5REVIEW_NARRATIVECited in: Long-term and Definitive Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Complications - [247]
Gritter M, Wouda RD, Yeung SMH et al.. “Effects of Short-Term Potassium Chloride Supplementation in Patients with CKD.” Journal of the American Society of Nephrology : JASN (2022). PMID: 35609996 ↗
L2OTHERCited in: Long-term and Definitive Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Complications, Special Populations and Prevention - [248]
Lazelle RA, McCully BH, Terker AS et al.. “Renal Deletion of 12 kDa FK506-Binding Protein Attenuates Tacrolimus-Induced Hypertension.” Journal of the American Society of Nephrology : JASN (2015). PMID: 26432904 ↗
L4OTHERCited in: Long-term and Definitive Management - [249]
Dos Santos ECB, de Souza Lima Bitar Y, Dos Anjos JLM et al.. “The impact of a potassium-enriched salt substitute on blood pressure control in patients with resistant arterial hypertension: A randomized pilot trial.” Contemporary clinical trials (2026). PMID: 41571229 ↗
L1RCTCited in: Long-term and Definitive Management, Special Populations and Prevention - [250]
Ji S, Vicas M, Franz A et al.. “Arterio-venous metabolite and electrolyte responses to low-load training with and without blood flow restriction versus high-load training to failure.” European journal of applied physiology (2025). PMID: 41359275 ↗
L1RCTCited in: Long-term and Definitive Management - [251]
Abouelmagd AA, Ramadan S, Sayed MS et al.. “Efficacy and safety of lorundrostat in uncontrolled hypertension: a meta-analysis.” Naunyn-Schmiedeberg's archives of pharmacology (2025). PMID: 41251750 ↗
L1SR_OBSCited in: Long-term and Definitive Management - [252]
Jaisser F, Barrera-Chimal J. “Mineralocorticoid receptor antagonism for non-diabetic kidney disease.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2025). PMID: 39907538 ↗
L5REVIEW_NARRATIVECited in: Long-term and Definitive Management - [253]
Sica DA. “Diuretic use in renal disease.” Nature reviews. Nephrology (2011). PMID: 22183505 ↗
L5REVIEW_NARRATIVECited in: Long-term and Definitive Management - [254]
Kamrul-Hasan ABM, Chatterjee S, Nagendra L et al.. “Safety and efficacy of lorundrostat, an aldosterone synthase inhibitor, in patients with uncontrolled hypertension: A systematic review and meta-analysis.” Medicine (2026). PMID: 42260805 ↗
L1SR_OBSCited in: Long-term and Definitive Management - [255]
Chen N, Hao C, Peng X et al.. “Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis.” The New England journal of medicine (2019). PMID: 31340089 ↗
L1RCTCited in: Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management - [256]
Weise WJ, Serrano FA, Fought J et al.. “Acute electrolyte and acid-base disorders in patients with ileostomies: a case series.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2008). PMID: 18562060 ↗
L4CASE_REPORTCited in: Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Special Populations and Prevention - [257]
Hamid AK, Pastor Arroyo EM, Calvet C et al.. “Phosphate Restriction Prevents Metabolic Acidosis and Curbs Rise in FGF23 and Mortality in Murine Folic Acid-Induced AKI.” Journal of the American Society of Nephrology : JASN (2024). PMID: 38189228 ↗
L4OTHERCited in: Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Prognosis and Natural History, Special Populations and Prevention - [258]
Simmer PE, Perza M, Cho YD et al.. “Hyperkalemic emergency department patients intubated with rocuronium or succinylcholine: Retrospective study of clinical outcomes.” The American journal of emergency medicine (2025). PMID: 41380422 ↗
L3COHORTCited in: Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management - [259]
Sohara E, Uchida S. “Kelch-like 3/Cullin 3 ubiquitin ligase complex and WNK signaling in salt-sensitive hypertension and electrolyte disorder.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2015). PMID: 26152401 ↗
L5REVIEW_NARRATIVECited in: Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management - [260]
Silva AKFD, Oliveira AG, Marques DP et al.. “Catecholamines and serum potassium alterations in critically ill neonates: a prospective cohort study.” Critical care science (2026). PMID: 41849521 ↗
L2COHORTCited in: Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management - [261]
Tu KC, Weng YC, Liao CT et al.. “The effectiveness and safety of sacubitril/valsartan in real-world dialysis patients with heart failure reduced ejection fraction.” Medicine (2026). PMID: 41630233 ↗
L2SR_OBSCited in: Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management - [262]
Rossignol P, Frimat L, Zannad F. “The safety of mineralocorticoid antagonists in maintenance hemodialysis patients: two steps forward.” Kidney international (2019). PMID: 30904064 ↗
L5OTHERCited in: Prognosis and Natural History - [263]
Dibo P, Mareddy NSR, Kojima GSA et al.. “Efficacy and safety of mineralocorticoid receptor antagonists in kidney transplant patients: an updated meta-analysis of randomized controlled trials.” BMC nephrology (2025). PMID: 40770304 ↗
L1SR_MA_RCTCited in: Prognosis and Natural History - [264]
Wen CF, Chuang MH, Wu VC et al.. “Efficacy of combined sodium-glucose cotransporter 2 inhibitors and finerenone in chronic kidney disease: a systematic review and meta-analysis.” Frontiers in pharmacology (2026). PMID: 42212277 ↗
L1SR_OBSCited in: Prognosis and Natural History - [265]
Pozueco Zaffari G, Noguero Duarte L, Queiroz I et al.. “Effectiveness of Sodium Bicarbonate Administration in Out-of-Hospital Cardiac Arrests: An Updated Systematic Review and Meta-Analysis.” Prehospital emergency care (2025). PMID: 41091632 ↗
L1SR_OBSCited in: Prognosis and Natural History - [266]
Meng Y, Zhang JW, Zhang YJ et al.. “Associations between Carvedilol Use and Outcomes in Critically Ill Patients with Acute Kidney Injury: A Multicenter Retrospective Cohort Study.” American journal of nephrology (2025). PMID: 41452793 ↗
L3COHORTCited in: Prognosis and Natural History - [267]
Byrne C, Krogager ML, Kragholm K et al.. “The association between arrival potassium and 30-day survival following resuscitation from out-of-hospital cardiac arrest: a retrospective cohort study.” Scandinavian journal of trauma, resuscitation and emergency medicine (2025). PMID: 40859315 ↗
L2COHORTCited in: Prognosis and Natural History - [268]
Tuot DS, Plantinga LC, Hsu CY et al.. “Chronic kidney disease awareness among individuals with clinical markers of kidney dysfunction.” Clinical journal of the American Society of Nephrology : CJASN (2011). PMID: 21784832 ↗
L2OTHERCited in: Prognosis and Natural History - [269]
Kohan DE, Fioretto P, Tang W et al.. “Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control.” Kidney international (2013). PMID: 24067431 ↗
L1RCTCited in: Special Populations and Prevention - [270]
Frimodt-Møller M, Høj Nielsen A, Strandgaard S et al.. “Feasibility of combined treatment with enalapril and candesartan in advanced chronic kidney disease.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2009). PMID: 19903661 ↗
L1RCTCited in: Special Populations and Prevention - [271]
Luciano RL. “Acute kidney injury from cherry concentrate in a patient with CKD.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2013). PMID: 24290246 ↗
L4CASE_REPORTCited in: Special Populations and Prevention